WO2007127209A2 - Methods and devices for gastrointestinal stimulation - Google Patents

Methods and devices for gastrointestinal stimulation Download PDF

Info

Publication number
WO2007127209A2
WO2007127209A2 PCT/US2007/009956 US2007009956W WO2007127209A2 WO 2007127209 A2 WO2007127209 A2 WO 2007127209A2 US 2007009956 W US2007009956 W US 2007009956W WO 2007127209 A2 WO2007127209 A2 WO 2007127209A2
Authority
WO
WIPO (PCT)
Prior art keywords
gastrointestinal
sleeve
stimulation system
stimulator
gastrointestinal stimulation
Prior art date
Application number
PCT/US2007/009956
Other languages
French (fr)
Other versions
WO2007127209A3 (en
Inventor
Bobby Griffin
Mitchell Dann
Greg Fluet
Original Assignee
Valentx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valentx, Inc. filed Critical Valentx, Inc.
Publication of WO2007127209A2 publication Critical patent/WO2007127209A2/en
Publication of WO2007127209A3 publication Critical patent/WO2007127209A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36007Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/378Electrical supply
    • A61N1/3787Electrical supply from an external energy source

Definitions

  • the invention relates generally to stimulation of the gastrointestinal tract with implanted electrodes.
  • Gastrointestinal sleeve devices for treatment of obesity have been described in prior applications, as have various devices and methods for attachment of a gastrointestinal sleeve device within a patient's digestive tract.
  • the present invention is directed to methods and devices for implantation of at least one electrode within the gastrointestinal tract, to deliver electrical stimulation.
  • a gastrointestinal stimulation system that includes a gastrointestinal bypass sleeve and an electrical stimulator component.
  • the electrical stimulator component is attached to the sleeve.
  • the system can also include a gastrointestinal attachment cuff having a tubular body, a proximal end and a distal end.
  • the electrical stimulator component can include a circuit board and a battery; a conductive element; and at least one electrode.
  • the stimulator component includes at least about two, three, four, five, or more electrodes.
  • a first and a second electrode can be spaced at least about lcm, 2cm, 3cm, 4cm, 5cm, 10cm, 15cm, 20cm, or more apart in some embodiments. In other embodiments, a first and a second electrode can be spaced apart between about l-20cm, 2- 10cm, 3-8cm, or 3-5cm.
  • the battery is configured to be recharged using RF energy.
  • the conductive element can be a ribbon.
  • the ribbon can have a U-shaped, S-shaped, or linear cross-section.
  • the circuit board and battery can be hermetically sealed in a base housing.
  • the base housing can be attached to the outer diameter of the sleeve, or the inner diameter of the sleeve.
  • the electrical stimulator can be triggered by a sensor configured to detect pressure, temperature, pH, motion, and/or strain.
  • the electrode can be annular band- shaped.
  • the conductive element is a lead wire.
  • the system includes at least one biasing element operably connected to an electrode. The biasing element can be configured to increase one of the contact surface area or the contact surface time between the electrode and a lumen of the gastrointestinal tract.
  • the biasing element is configured to increase the contact surface area between the electrode and a lumen of the gastrointestinal tract.
  • the biasing element is a continuous helical band.
  • the biasing element is a ring.
  • the biasing element can be a flexible tube, and the electrode is positioned on an outer surface of the tube.
  • the gastrointestinal bypass sleeve is at least partially inverted within itself, and adapted for eversion within the gastrointestinal tract.
  • a gastrointestinal stimulation system that includes a electrical stimulator component, the stimulator component comprising a circuit board and a power source contained within a base housing; a conductive element; and at least one electrode; wherein the stimulator component is configured to be transmurally attached with a plurality of tissue anchors to a wall of the gastrointestinal tract.
  • Also disclosed herein is a method of treating a patient, including the steps of providing an electrical stimulator component, the stimulator component comprising a circuit board and a power source contained within a base housing; a conductive element; and at least one electrode; positioning the base housing of the electrical stimulator component in the patient's digestive tract such that the base housing is positioned in the vicinity of the gastroesophageal junction; securing the base housing to a structure in the vicinity of the gastroesophageal junction, positioning the electrode within the intestine such that the electrode contacts the wall of the intestinal lumen; and stimulating the intestinal lumen.
  • the securing step can include advancing at least one, two, three, four, or more tissue anchors through the tissue wall and positioning a retention surface on each tissue anchor in contact with the serosal surface.
  • Also disclosed herein is a method of treating a patient, including the steps of providing a gastrointestinal sleeve device having an elongate tubular body, with a proximal end and a distal end; providing an electrical stimulation component comprising: a circuit board and a battery contained within a base housing; a conduction element; and at least one electrode operably attached to the sleeve device; positioning the gastrointestinal sleeve device in the patient's digestive tract such that the proximal end of the tubular body is positioned in the vicinity of the gastroesophageal junction to receive ingested material from the patient's esophagus and the distal end of the tubular body is positioned in the patient's intestine; positioning the base housing in the vicinity of the gastroesophageal junction; securing the proximal end of the sleeve device and the base housing of the electrical stimulator component in the vicinity of the gastroesophageal junction; securing the base housing of the
  • a method of treating a patient including the steps of providing a gastrointestinal sleeve device having an elongate tubular body, with a proximal end and a distal end; providing an electrical stimulation component comprising: a circuit board and a battery contained within a base housing; a conduction element; and at least one electrode; positioning the gastrointestinal sleeve device in the patient's digestive tract; positioning the base housing in the patient's gastrointestinal tract; and treating a patient using both the bypass sleeve and the electrical stimulator device.
  • the base housing can be operably attached to the sleeve. In some embodiments, positioning of the electrical stimulation device and the gastrointestinal sleeve device does not occur during the same procedure.
  • the method can also include the steps of providing a gastric space-filling device operably attached to the base housing of the electrical stimulation component; and deploying the space-filling device within the stomach.
  • the space-filling device is a balloon, solid implant, or a bezoar.
  • FIG. 1 schematically illustrates one embodiment of a gastrointestinal stimulation system that includes a cuff, sleeve, and electrical stimulation component including a plurality of annular band electrodes.
  • FIG. 2 schematically illustrates an embodiment of a gastrointestinal stimulation system that includes biasing elements in the form of rings, to increase contact surface area and/or time of electrodes to the intestinal lumen.
  • FIG. 3 schematically illustrates an embodiment of a gastrointestinal stimulation system that includes biasing elements in the form of a helical band, to increase contact surface area and/or time of electrodes to the intestinal lumen.
  • FIG. 4 schematically illustrates an embodiment of a sleeveless gastrointestinal stimulation system.
  • FIG. 5 schematically illustrates an attachment mechanism for a gastrointestinal stimulation system, in one embodiment of the invention.
  • FIGS. 6-8A schematically illustrate cross-sections of various embodiments of ribbon electrodes, according to some embodiments of the invention.
  • FIG. 9A schematically illustrates a cuff-less, sleeveless gastrointestinal stimulation system where the base stimulator is directly attached to a wall of the GI tract, according to one embodiment of the invention.
  • FIG. 9B schematically illustrates a gastrointestinal stimulation system where the base stimulator is attached to a gastric balloon, according to one embodiment of the invention.
  • FIGS. lOA-C schematically illustrate steps showing toposcopic delivery of a gastrointestinal stimulation system, according to one embodiment of the invention.
  • FIG. 11 schematically illustrates a system for pressurizing a toposcopically deliverable sleeve, according to one embodiment of the invention.
  • FIGS. 12A-B illustrate a toposcopic deployment system that can be used to deliver a gastrointestinal stimulation system, according to some embodiments of the invention.
  • FIG. 13 A illustrates a possible attachment site for a gastrointestinal stimulation system, according to some embodiments of the inventions.
  • FIGS. 13B-13D illustrate a possible model of tissue ingrowth following transmural T-tag implantation, according to some embodiments of the invention.
  • FIGS. 13E-19D illustrate attachment mechanisms, including T-tags and T- pledgets that can be used for a gastrointestinal stimulation system, according to some embodiments of the invention.
  • the present invention provides methods and devices for implantation of at least one electrode within a body lumen, which may be the gastrointestinal tract, to deliver electrical stimulation.
  • the electrodes may be supported by an endolumenal bypass sleeve, or by an attachment cuff, as have been described in United States Patent Application Serial No. 10/698,148, filed 10/31/03, published 5/13/04 as U.S. Patent Pub. No. 2004-0092892 Al and entitled "APPARATUS AND METHODS FOR TREATMENT OF MORBID OBESITY" (and may be referred to herein as the "Kagan ' 148 Application”); United States Patent Application Serial No.
  • the electrodes may alternatively be attached to nontubular support structures such as an elongate flexible ribbon or tether, which is in turn attached to the wall of the GI system using the transmural anchoring techniques disclosed in the above referenced patent applications.
  • the structure could be held in place via non-transmural devices that resist the natural tendency of the GI tract to expel devices from the system.
  • suitable non- transmural devices include gastric balloons and bezoars or other devices large enough to resist passage through the pylorus or out through the esophagus once implanted in the stomach.
  • Other devices include stent like structures placed either in the esophagus or the stomach that may hold the stimulator in place through apposition of the structure to the stomach or luminal wall. These devices could also be placed inside or past the pylorus.
  • a gastrointestinal (GI) stimulation device in some embodiments, preferably includes a power source, such as a battery, and is used to deliver energy to any portion of the GI tract, such as a lumen. In some embodiments, the energy is preferably not delivered to the stomach even though the device may be attached in the stomach or the gastro-esophageal junction.
  • a power source such as a battery
  • the device is intended to treat obesity, any of the co-morbidities associated with obesity including diabetes; GI inflammatory diseases (e.g., Crohn's disease, ulcerative colitis, celiac sprue), GI hypermotility and well as hypomotility disorders (e.g., gastroparesis, ileus, bowel obstructions, achalasia, irritable bowel syndrome, Hirschprung's disease, toxic megacolon, Ogilvie's syndrome), malabsorptive disorders, and any other disease with manifestations involving the GI tract.
  • GI inflammatory diseases e.g., Crohn's disease, ulcerative colitis, celiac sprue
  • hypomotility disorders e.g., gastroparesis, ileus, bowel obstructions, achalasia, irritable bowel syndrome, Hirschprung's disease, toxic megacolon, Ogilvie's syndrome
  • malabsorptive disorders e.g., malabsorptive disorders, and any other disease
  • the electrodes would preferably stimulate the lumen distal to the stomach. They could be placed in the pylorus, duodenum, ileum, jejunum, colon or any combination of these sections of the GI tract. In other embodiments, the electrodes could stimulate the lumen of the stomach or esophagus. In still other embodiments, the electrodes could stimulate the lumen of the biliary tree, such as the common bile duct, cystic duct, hepatic duct, or pancreatic duct; or other structures such as the sphincter of Oddi.
  • the stimulation could be used to reduce the feeling of hunger or it could increase or decrease the rate of peristalsis to increase or decrease the rate at which food passes or it may act to accelerate or inhibit absorption of digested material by increasing or reducing the activity of the active transport mechanisms in the intestinal wall.
  • the stimulator could operate on a constant program, variable program, or a sensor that detects the intake of food and/or liquid could trigger a stimulation program. If it is triggered by a sensor detecting intake of foods and/or liquid it could be preset to run for a specific period of time following that triggering mechanism.
  • Variables that could be detected by the sensor include pressure, temperature, motion, strain or pH to indicate the intake of food or liquid.
  • the electrical stimulator would include a power source, a circuit board, a conductive element, and at least one electrode configured to transmit the energy to the lumen.
  • the power source is most preferably a battery.
  • the circuit board is most preferably a printed circuit board, although wire-wrapped or point-to-point constructed circuits could also be used.
  • the battery and printed circuit board could be, in some embodiments, part of the cuff or part of the sleeve.
  • the battery and circuit board are part of the sleeve, they could be near the intake end of the sleeve or alternatively could be placed at a distance from the intake end, such as past the pylorus, to help reduce any direct weight on the anchor points or cuff/sleeve attachment.
  • the circuit board and power source are most preferably hermetically sealed together in an electrical stimulator base housing.
  • One way to seal the housing of the device would be to encase it in a metal foil.
  • the printed circuit board would preferably generate an oscillating circuit that would be used to drive the stimulator.
  • the voltage, pulsewidth, frequency and duty cycle can be programmable, or they could be preprogrammed before implantation.
  • the electrical stimulator preferably has a preset operating frequency and period which can vary according to the alteration of stomach motility to be obtained and/or to the pathological condition of the patient.
  • the electrical stimulator has an operating frequency of about 2 to about 30 pulses per minute.
  • the process of this invention employs stimulation of the small intestines at a rate of about 2 to about 30 pulses/minute with each pulse lasting about 0.1 to about 4 seconds such that there is a pause of about 3 to about 30 seconds between the pulses.
  • the electrical discharge of each pulse can vary from approximately 1 to 15 volts for voltage-controlled stimulation and from 2 to 15 milliamperes for constant current stimulation.
  • the pulse rate is about 12 to about 14 pulses/minute with each pulse lasting about 0.1 to about 0.5 seconds with a pause of about 4.5 to about 5 seconds between pulses.
  • the pulse amplitude is about 0.5 to about 15 milliamps.
  • each pulse consists of a train of micro-bursts with a frequency of about 5 to about 100 Hz.
  • the stimulator base housing would preferably be placed on the outside diameter of the sleeve so it would not interfere with food passing through the sleeve, however it could also be sealed between layers of the sleeve material. This may help further protect the stimulator from any exposure to stomach acid or other material.
  • Figure 1 illustrates a gastrointestinal stimulation system 1 that includes a gastrointestinal sleeve device 100 attached to an artificial attachment cuff or stoma device 102 implanted within a patient's stomach 104.
  • the attachment cuff 102 can be implanted in the vicinity of the gastroesophageal junction 106, or at the outlet of a surgically created gastric pouch (not illustrated).
  • the attachment cuff 102 preferably does not restrict the flow of food, although it may be provided with a restrictive opening if desired.
  • the cuff 102 can have a fixed diameter opening 108 equal to, larger or smaller than the fully open diameter at the native GEJ.
  • the cuff 102 can have an adjustable stoma opening or it can be a "smart" stoma that adjusts the size of the stoma opening in response to various conditions.
  • the attachment cuff 102 is preferably configured for peroral delivery and attachment using endoscopic techniques.
  • the cuff 102 can be implanted using laparoscopic or open surgical techniques. Additional details of the cuff, stoma and attachment can be found, for example, in any of the related applications incorporated by reference herein, such as, for example, the Dann '605 application.
  • the stimulation system 1 shown in Figure 1 also includes an electrical stimulation component 3 including a battery 2 and circuit board 4 preferably hermetically sealed within in a base housing 6. As illustrated, the base of the stimulation component 6 is shown closer to the greater curve 7 of the stomach 104.
  • the base housing 6 of the device 3 may be placed at any location on the circumference of the sleeve 100 and there may be advantages to being placed on the lesser curve 8 side of the circumference, or any other aspect of the sleeve 100.
  • the stimulator base 6 could be attached to the sleeve at some distance farther away from the cuff 102 than depicted in the drawing, e.g., at least about 25cm, 50cm, 75cm, 100cm, 125cm, or more.
  • the electrical stimulation component 3 preferably also includes a conductive element 10, which can be a lead wire in some embodiments, and that, as depicted in FIG. 1, could be a bundle of multiple wires to individually power one or more electrodes 12. Alternatively, there could be more than one electrode 12 per wire 10. The optimal configuration would be driven by the desired stimulation program.
  • the electrodes 12 shown in FIG. 1 can be in the shape of an annular band that can partially or fully circumscribe a portion of the sleeve 100. However, various other sized and shaped electrodes are contemplated as well. Alternatively, the electrodes could be connected wirelessly to the stimulator.
  • the battery 2 for the stimulation component 3 could be relatively small, as the sleeve 100 is not necessarily designed as a permanent implant, although permanent implants are also contemplated.
  • a stimulation component's specified energy and lifespan of the device with a battery is described below.
  • the lifetime of that battery 2 would be equal 2 x 10 6 seconds, or about 23 days. If a longer battery life is desired, a 135 milliampere battery would advantageously increase the battery lifetime by 50%. Batteries in this size would be approximately of that found in watches or calculators.
  • the electrode(s) 12 of a stimulation component 3 would most preferably contact the inside wall of the lumen. This means some exposed part of the electrode 12 would need to be on the outside surface of the sleeve 100 or if there is no sleeve 100 exposed to the inner surface of the mucosal lining of the lumen. Contact with the lumen can be achieved with a variety of means. In a preferred embodiment, barbs or other forms of fixed attachment to the intestinal wall are not used as this could provide the intestines with a point to pull on the device 3 and cause complications such as an accordion-like response in the intestine, potentially resulting in intussception or volvulus, rupture of the intestinal wall, or detachment of the device's anchor mechanisms. Other embodiments disclosed herein illustrate various different non-limiting electrode shapes and configurations.
  • the electrodes 12 will typically have sufficient contact with the luminal wall because of the natural tendency for the lumen to close down on whatever is in it.
  • the electrodes 12 could be a raised form such as pyramid, hemisphere or mushroom shaped to help create better contact.
  • electrodes 12 can be placed in contact with the luminal surface, in some embodiments one or more electrodes 12 can be placed on the serosal surface, or even some electrodes 12 in contact with the luminal surface while other electrodes 12 are in contact with the serosal surface.
  • a stimulation system can involve any number of electrodes 12 depending on the desired clinical result.
  • a stimulation system has at least about 1, 2, 3, 4, 5, 10, 15, 20, or more electrodes 12.
  • the electrodes 12 can also be spaced apart any appropriate distance depending on the desired clinical result.
  • a first electrode may be spaced apart from a second electrode by between about l-20cm, preferably between about 2-1 Ocm, in some embodiments between about 3-8cm, in other embodiments between about 3 -5cm.
  • FIG. 2 illustrates a gastrointestinal stimulation system 14 similar to that of FIG. 1, and including one or more biasing elements 16.
  • the biasing elements 16 as shown schematically in FIG. 2 is a series of one or more rings 16 biased towards an expanded state that are connected by a wire 10 to power the electrodes 12 that are on the rings 16. There could be one or more electrodes 12 on each ring 16. Using rings 16 as biasing elements 16 would be preferable when there is the desire to place multiple electrodes 12 at one circumferential area of the intestine 114.
  • FIG. 3 illustrates a gastrointestinal stimulation system 15 where the biasing element is a helical support structure 18 that runs part of or all of the length of the sleeve 100.
  • the one or more electrodes 12 are most preferably attached to the helical support structure 18.
  • One possible advantage of a helical support structure 18 that is biased towards an expanded state is that, unlike with the rings 16 shown in FIG. 2, there would not be a ring or oval shaped device for the peristaltic contraction to 'pull' on, if this is a factor to consider, as it would tend to collapse as necessary when compressed, but still maintain contact with the lumen.
  • any support structure of the sleeve 100 described in any of the prior applications incorporated by reference, such as the Dann '605 application could also incorporate electrodes 12 in its design.
  • a biasing element 16 could be made, at least in part, of a super elastic metal, such as Nitinol, other shape meory material, or could be made from plastic or could be a combination of both where the core is Nitinol and they are surrounded by or partially surrounded by a plastic. In this case the plastic could also serve as an insulator where desired.
  • a super elastic metal such as Nitinol, other shape meory material
  • the electrical stimulation component 3 could be pre-programmed before placement. There could be a separate programmer remote from the stimulator 3 that could control any of the aspects of the stimulation cycle and/or triggering mechanism of the device wirelessly from outside the patient.
  • the stimulator with one preset program could be used initially. Then, after a certain time, a device with a different program could be switched out. This could occur when replacing the sleeve 100 if the stimulator component 3 is integrated with the sleeve 100.
  • the stimulation program may be varied using the length of the sleeve 100 as a variable and what points of contact in the GI tract are expected to exist with the modified length of tubing. For example, the stimulator component 3 may deliver more energy if there is a shorter sleeve 100 and the stimulator component 3 could deliver less energy through each electrode 12 if there is a longer sleeve 100 or any such combination of these variables could be used.
  • the battery 2 could be recharged wirelessly by an external power source that uses RF energy transmitted through the body to recharge the battery 2, such as transcutaneously.
  • a terminal is present on the cuff 102 that could be accessed trans-orally to recharge the battery through direct conduction. This could be done during routine follow up with a diagnostic endoscopic procedure to inspect the system in place.
  • the battery 2 could be a simple disposable battery that is configured to run out of charge at or near the time of a scheduled sleeve removal or replacement.
  • One of ordinary skill in the art will appreciate that a wide variety of battery 2 types can be selected for use with the disclosed stimulation systems.
  • the stimulator component 3 as described above could also be separate from the sleeve element 100 of the system.
  • a gastrointestinal stimulation system 40 does not include a sleeve element 100. This would allow for a variety of treatment options.
  • the electrical stimulator base unit 6 could be attached to the cuff 102, such as tethered to the cuff 102, and the electrodes 12 could be on a ribbon 24 or other device that is advanced down the GI tract, as shown in FIG. 4.
  • the ribbon 24 that holds the electrodes 12 could have a shape that would help bias the electrodes 12 into contact with the lumen.
  • a compliant ribbon 24 may have enough contact with the lumenal wall because of the tendency of the intestine 1 14 to collapse into a flat configuration.
  • the ribbon 24 may take on a predefined shape such as a helix through the use of reinforcement elements in the ribbon 24.
  • the electrodes 12 would be oriented to be on the outside of the helical surface of the ribbon 24.
  • These could be stiffer plastic materials or super elastic metals such as JNitinol used to make the helical structure.
  • the ribbon 24 itself may be of a material that could be shape set into this configuration.
  • FIG. 6 illustrates a ribbon 50 with a U shaped cross-section. Ribbons preferably have first and second sides. Electrodes 12 are shown operably attached to the ribbon 50. One end of ribbon connects to the base unit 6 of the stimulation element.
  • FIG. 7 illustrates a ribbon 52 with an S-shaped cross-section. Such an embodiment can have electrodes 12 on both first and second sides of the ribbon 52 as shown.
  • the U shaped 50 or S shaped 52 cross sections as depicted in FIGS.
  • FIG. 8 illustrates an embodiment where the ribbon 54 is substantially flat. Attached to ribbon 54 are electrodes 12 on both the first and second sides of the ribbon 54. In some embodiments, electrodes 12 may be only on either the first or second side of the ribbon 54. Arrows 51, 53, 55, 57 of FIGS. 6-8A, respectively, illustrate a direction in which an end of the ribbon 50, 52, 54 connect to base 6 of stimulator component 3.
  • FIG. 8A illustrates a ribbon 56 with operably connected electrodes 12 similar to that shown in FIG. 8A 3 also having a lumen 58.
  • Lumen 58 is preferably configured to allow a stiffening element (not shown) to pass therethrough in order to provide additional structural support for the ribbon 56.
  • the stiffening element is a guidewire.
  • the guidewire may have a shape memory material such as Nitinol to allow for possible adjustment should a change in the degree of stiffening be required.
  • Any of the sleeves, such as sleeve 100 disclosed herein can also have one or more lumens (in addition to the artificial stoma for bypass of food contents, etc.) present that are configured to receive a stiffening element.
  • the ribbon 24 can have a protrusion, bulge, or balloon (not shown) in its construction on or near the distal end to help transfer a desired amount of force from the peristaltic contractions to help keep the ribbon 24 in place.
  • FIG. 5 shows one embodiment of a fastener 660 comprising a hanger 661 that also functions to hold two layers of folded tissue together.
  • the fastener 660 may be used to secure the base unit 6 of the stimulation component 3 to the mucosal wall.
  • Many other suitable fasteners are disclosed, for example, in the Kagan '634 application.
  • the fastener 660 of FIG. 5 has a toggle 662 that pivots on a hinge 663 so that is can be aligned with the post 664 as it is passed through tissue layers, and can then be pivoted to hold the tissue layers together.
  • the toggle 662 helps to distribute forces that hold the fastener 660 in place over the length of the toggle 662, and also prevents the fastener 660 from being pulled through the hole.
  • a similar functioning apparatus such as a disc or a multi-arm umbrella could also be used to distribute forces on the adjacent tissues while preventing the fastener 660 from passing through the hole.
  • This fastener functions similarly to the T-tag fasteners described herein.
  • the electrodes 12 could be on the outside of a flexible tube (not shown).
  • the tube could be hollow or solid as desired.
  • the diameter of the tube would be ideally just large enough to allow good contact with the lumen of the intestine but not too large to cause any reaction in the intestine or risk occluding the intestine.
  • the ends of the tube would most preferably not be open to keep any food or material from impacting in the tube.
  • a hollow or solid tube could have any of the structural elements as conceived for the sleeve as previously described, for example, spiral reinforcements, ribs, or a larger node near the distal end to help capture force from the peristaltic motion of the intestines.
  • the tube could have shape set into the lube itself during manufacturing to give it a preferred structure.
  • the tube could form a helical structure to bias an outer surface of the helix into contact with the lumen.
  • the center of the helical structure could be large enough to allow a cuff/sleeve system to be implanted through the center of it. In this way a sleeve could be initially implanted but then removed after a certain period of time and just the stimulator would remain. Alternatively, the stimulator could be removed and the sleeve could remain. In still other embodiments, one of the stimulator or the sleeve could be implanted first and then the other device could be added after a certain period of time
  • FIG. 9A One such stimulation system 90 is shown in FIG. 9A.
  • the stimulator could be attached directly to a subsection of the GEJ with transmural anchors as described in, for example, the Kagan '634 or Dann '605 applications.
  • an attachment or fastener device 651 for the base stimulator 6 can be driven through a single tissue layer, with attachment means 654 on the end of a post 653 positioned within the passageway, and a cone shaped spring positioned 652 on the serosal side.
  • FIG. 9A an attachment or fastener device 651 for the base stimulator 6 can be driven through a single tissue layer, with attachment means 654 on the end of a post 653 positioned within the passageway, and a cone shaped spring positioned 652 on the serosal side.
  • FIG. 9A is preferably configured so that its installation does not narrow the passageway of the organ. Delivery of fastener embodiments communicating with the exterior of a hollow organ as shown in FIG. 9A may incorporate means to control capture of other structures. Though it may be clinically desirable to capture other structures as in the case of capturing the diaphragm by fasteners placed in the cardia of the stomach it is more likely that this would be undesirable.
  • Fastening means could incorporate shielding means and/or means to invaginate the organ wall as the fastener is advanced through the organ wall.
  • FIG. 9A Also shown in FIG. 9A is a conductive element 24 operably attached to the base stimulator 6 at its proximal end, and having electrodes 12 operably attached to the conductive element 24 within the intestine more distally as shown.
  • the conductive element 24 can be a ribbon as shown in FIG. 4.
  • the base stimulator 6 may be attached to the fastener illustrated in FIG. 5.
  • the base stimulator 6 could be on a device 60 configured to remain in place in the stomach 104 without transmural attachment of device 60 to the stomach 104.
  • Space-occupying devices such as gastric balloons or bezoars are known to those in the art. These are devices that are designed to remain in the stomach after implantation.
  • a stimulator base 6 as described could be attached to such a device 60 or inside the device 60 and the ribbon, tether, or the like holding the electrodes 12 in place would be attached either to the anchoring device 60 and/or the base stimulator 6 itself.
  • there could be a cuff and/or sleeve device (sleeve shown as 12 in FIG.
  • Electrodes 12 are preferably raised on top of a helically-biased tube 62 (which may be the conductive element 10, or could alternatively serve as a scaffolding for a lead wire in some embodiments) separate from, but wrapped around the outer diameter of the sleeve 100.
  • a helically-biased tube 62 which may be the conductive element 10, or could alternatively serve as a scaffolding for a lead wire in some embodiments
  • a preferred location to attach the base 6 of the stimulator component 3 is selected.
  • the side of the GEJ closest to the lesser curve of the stomach may have characteristics such as lesser motility or a different type of tissue that makes it better to attach the stimulator base 6.
  • the part of the GEJ closest to the lesser curve of the stomach can be an ideal place to attach other devices in the stomach besides a stimulator. It could be an advantageous anchor point for volume occupying devices or other sensors to monitor physiologic parameters such as pH.
  • the ribbon type electrode as described above could be used, or any other type of flexible connector for connecting the intestinal electrodes to the stimulator
  • a gastrointestinal stimulation system can be placed in a patient using a toposcopic delivery method, such as a method similar to that disclosed in the Dann '605 application.
  • a toposcopic delivery method such as a method similar to that disclosed in the Dann '605 application.
  • Other useful devices and methods for toposcopic access and delivery are disclosed in U.S. Provisional Patent Application No. 60/826,862 to Dann et al., filed on September 25, 2006 and hereby incorporated by reference in its entirety.
  • Embodiments of gastrointestinal stimulation systems that are configured to be delivered toposcopically most preferably include electrodes operably attached to sleeve elements, such as, for example, the embodiments illustrated in FIGS. 2 and 3.
  • toposcopic delivery of other embodiments, such as wireless electrodes is also possible.
  • toposcopic delivery of sleeve 100 with attached electrodes 12 is achieved by performing the following steps:
  • cuff 102 optionally attach cuff 102, if a cuff is part of the gastrointestinal stimulation system (not shown), as disclosed above, as well as, e.g., in the Dann '605 application.
  • Base 6 of the stimulator component 3 can be held in a fixed position in a filling catheter 400, and later attached to the cuff 102 after complete eversion of the sleeve 100 in some embodiments.
  • the attachment anchors for attaching cuff 102 to tissue in the vicinity of GEJ 106, as well as conductive element 10 of the electrical stimulator component 3 are not shown.
  • Attach sleeve 100 that can include electrodes 12, biasing elements 16, base stimulator 6, and conductive element 10 (not shown) as described above, to filling catheter 400, invert sleeve 100 within the filling catheter, and create a fluid-tight seal 468 between the sleeve 100 and filling catheter 400, if these steps have not been previously done.
  • FIG. 1OA shows the proximal end of sleeve 100 and the distal end of filling catheter 400 deployed in stomach 104, with distal end 112 of sleeve 100 including electrodes 12 attached to biasing elements 18, retracted proximally within the filling catheter 400 at least as far as the esophagus 164. Also shown is stimulator base 6. Conductive element is not shown in FIGS. lOA-lOC for clarity.
  • FIG. 1OB shows sleeve 100 partially unraveled or otherwise deployed such that distal end 112 has advanced past GEJ 106.
  • FIG. 1OC shows sleeve 100 including biasing element 18 and attached electrodes 12 fully deployed down intestine 114.
  • the conductive element 10 of the stimulation component 3 is operably attached to a wall of the sleeve 100 to help prevent kinking of the conductive element 10 during eversion at the time of toposcopic delivery.
  • the biasing element 18 could be placed in the sleeve 100 after toposcopic delivery.
  • the electrodes 12 and conductive element 10 would be built into the wall of the sleeve 100 and could add very little stiffness to the construct to help facilitate toposcopic delivery.
  • the sleeve 100 may have a lumen built into or attached to the wall of the sleeve 100 that runs underneath the electrodes 12.
  • a biasing element 18 with a preformed shape could be inserted into the lumen and it would then help bias the electrodes 12 outwards towards the wall of the lumen.
  • This would be a helical lumen in the wall of the sleeve 100 underneath the electrodes 12.
  • the biasing element 18 could be, in one embodiment, a nitinol wire shaped to form a helix. The temperature of the wire could be lowered before insertion to make the wire as flexible as possible. When the wire rewarms to the ambient temperature in the lumen it would re-form its biased shape.
  • Sleeve 100 can be inverted one or more times to create multiple layers of sleeve that unravel during toposcopic delivery.
  • a sleeve 100 can have two, three, four, or more inversions.
  • sleeve 100 is inverted once.
  • FIG. 11 illustrates a method of using a filling catheter to facilitate toposcopic delivery.
  • filling catheter 400 such as a catheter described in the Dann '605 application
  • a device 416 that flushes filling catheter 400 with inflation media such as a fluid.
  • Device 416 can comprise, for example, an electronic or hand-actuated piston or plunger, hand pump, impeller pump, or peristaltic pump.
  • an endoscope can flush filling catheter 400 with fluid.
  • Device 416 can in turn be placed in fluid communication with a fluid source 420.
  • device 416 can be in fluid communication with a container 420 that holds fluid.
  • Container 420 can hold volumes of fluid ranging from 0.25 liters to 15 liters.
  • container 420 holds between one and five liters.
  • Device 420 can flush fluid through filling catheter 400 at a rate ranging from 5 cc to 100 cc per stroke or actuation of device 420. In preferred embodiments, device 420 flushes fluid through filling catheter 400 at a rate of 30 cc to 300 cc per stroke.
  • the filling catheter 400 or the device 416 can have a pressure or volume measurement device to measure the pressure or delivered volume of fluid that is used to evert the sleeve 100. This can be used as an alternative way to determine when the sleeve is fully deployed. The volume measurement can be used to determine when enough fluid has been delivered to fully deploy the sleeve 100. The pressure measurement can be used to detect the pressure drop once the sleeve is fully deployed and the distal end 112 of the sleeve opens up to allow the fluid to pass through with less back pressure.
  • filling catheter 400 passes into the lumen of sleeve 100 and a fluid-tight seal 468 is created between the proximal end of sleeve 100 and filling catheter 400, as shown in FIG. 11.
  • the distal end 112 of sleeve 100 passes proximally into the lumen of filling catheter 400, the proximal end of sleeve is concentrically positioned over the distal end of filling catheter 400, and a fluid-tight seal 468 is created between the proximal, inverted, outer surface of sleeve 100 and the distal end of filling catheter 400, as shown in Fig. 18.
  • Tubing 470 can be utilized to provide a passageway between filling catheter 400 and device 416.
  • a temporary barrier 466 can be created at distal end 112 of sleeve 100.
  • temporary barrier 466 is created by collapse of distal end 112 caused by the influx of fluid through filling catheter 400.
  • distal end 112 can be blocked with an absorbable or degradable plug comprising cellulose, sugar-based substances, PLA, and any other materials as would be contemplated by those skilled in the art. Any of the techniques discussed above can also be used to create temporary barrier 466.
  • Toposcopic delivery allows sleeve 100 to be delivered without moving electrodes 12 on sleeve 100 over and against the endothelium of the esophagus, stomach, and intestines.
  • Sleeve 100 when delivered toposcopically can navigate tortuous anatomy.
  • inverted portions of sleeve 100 deploy an axial elongation without axial sliding against the tissue such that there is no tissue abrasion and no kinks or twists are created in sleeve 100.
  • Toposcopic delivery of electrodes 12 also requires minimal instrumentation development.
  • the sleeve 100 delivered toposcopically is not limited to being attached to the cuff at the GEJ.
  • the method of delivering an intestinal sleeve with a toposcopic delivery technique as described above can be used to attach a sleeve to the pylorus, the duodenal bulb, the lower portion of the stomach or anywhere else where it is deemed to be clinically beneficial.
  • a GI sleeve containing electrodes 12 can be inserted and/or retrieved using a flexible endoscope.
  • a skilled GI endoscopist can "drive" a special endoscope (an enteroscope) through the duodenum and deep into the jejunum. Because of its small size, a pediatric colonoscope can be used to access an area further down the intestine.
  • the sleeve can piggyback on the endoscope as it is driven into the jejunum and then released with its distal end left in the jejunum when the endoscope is retracted and removed from the body. This can be accomplished perorally either before or after attachment of the proximal end of the sleeve to tissue or to a cuff at the GEJ 106 or some other clinically desirable location. Toposcopic Delivery without Retaining a Bypass Sleeve
  • all or part of the stimulation system may be delivered toposcopically without retaining a bypass sleeve within a body lumen after completion of the procedure.
  • the delivered device may be an electrical stimulation component or any part thereof, such as one or more electrodes, or an alternative access system such as a guidewire or rail.
  • the delivered device may be detached at the delivery site and left in place (an implant) or removed from the body following the diagnostic or therapeutic procedure.
  • FIG. 12A there is illustrated a toposcopic delivery device in accordance with the present invention.
  • the delivery device includes a filling catheter 400, illustrated as extending across the stomach such that a distal end 402 is in the vicinity of the pylorus 116.
  • a toposcopic delivery sleeve 1000 (which can, in some embodiments, be essentially the same as a bypass sleeve 100 except removed after the procedure) may be is proximally retracted within the filling catheter 400.
  • the distal end 112 of the toposcopic sleeve 1000 is closed, and provided with a connector 200. As illustrated in FlG. 12B and as will be apparent in view of the preceding discussion, the connector will advance distally in response to the introduction of inflation media through filling catheter 400.
  • the connector 200 may be removably or permanently connected to a device, such as, for example, a base stimulator, a biasing element, a conductive element, or an electrode, which maybe a wireless electrode.
  • a device such as, for example, a base stimulator, a biasing element, a conductive element, or an electrode, which maybe a wireless electrode.
  • the connector 200 is connected to a guidewire 152.
  • the connector 200 advances distally, pulling guidewire 152 in a distal direction.
  • a guidewire 152 may be distally axially advanced through a tortuous pathway, within the sleeve 100.
  • the connector 200 may be caused to release the guidewire 152. Release may be accomplished in any of a variety of ways, such as by introduction of a solvent through sleeve 1000, introduction of a solvent around the outside of the filling catheter 400, thermally releasing a polymeric link through the use of a monopolar or bipolar electrical circuit as is understood in the detachable intracranial aneurysm coil field, or the like.
  • the guidewire 152 may comprise a hollow outer sleeve which axially slideably receives an inner core. Axial, proximal or distal displacement of the core with respect to the sleeve can be utilized to detach the connector 200.
  • the guidewire may also be forceably detached, by a pushing, twisting or pulling motion.
  • the sleeve 1000 may be proximally retracted leaving the guidewire 152 in place.
  • devices may be advanced along the guidewire 152 through the sleeve 1000, leaving the sleeve 1000 in position.
  • a stimulation system as disclosed herein can be attached to the wall of the GI tract with any variety of fasteners known in the art.
  • a stimulation system is securing using fasteners disclosed in the Kagan '634 application, and discussed below.
  • the present inventors believe that some areas of the esophageal or gastric wall exhibit physical properties more conducive to retaining attachment structures than other areas.
  • an attachment zone 1600 shown in FIG. 13 A, directly below the squamocolumnar junction (SCJ) 1620, also known as the Z-line, ora serrata, and mucosal gastroesophageal junction (GEJ) 106, may be such an area.
  • the SCJ marks the junction of the squamous mucosa of the esophagus and the columnar or glandular mucosa of the stomach.
  • the SCJ is typically located at or above the GEJ.
  • At least a portion of a gastrointestinal stimulation system may, in one preferred embodiment, be attached in an attachment zone 1600 no more than about 2 cm and preferably no more than about 1 cm below the SCJ 1620 and below the esophagus 1640 where the tissue wall thickness is thicker than the tissue wall thickness of the esophagus 1640 and where there exists a serosal outer surface not exhibited at the esophagus 1640.
  • the device is also preferably attached at a location in the attachment zone 1600 so as to minimize the risk of reflux.
  • the SCJ 1620 can be located relative to other anatomical regions. It normally may be found at the GEJ 106.
  • the GEJ 106 is the region at which the tubular esophagus joins the saccular stomach.
  • the GEJ 106 can be considered the first part of the stomach 1660 or the cardia and is located at the proximal margin of the longitudinal gastric mucosal folds or in the distal 2 cm of the esophagus 1640 and proximal stomach 1660. Endoscopically, the location of the GEJ 106 can be approximated by identifying the proximal margin of the gastric folds.
  • a first aspect to the location of attachment of the devices disclosed herein relates to the position of the attachment structures along the axis of the hollow lumen or organ.
  • the attachment location in the axial direction is preferably in the vicinity of the gastroesophageal junction, and particularly just below the SCJ.
  • This attachment site can be located endoscopically by observing the color change which occurs at the SCJ, and advancing or positioning the attachment structures of the endoscope slightly below that line.
  • the gastroesophageal junction is a preferred attachment point for, for example a portion of a gastrointestinal stimulation system such as a gastroesophageal sleeve 100 or a stimulator base housing 6 as discussed above. Attachment at the GEJ 106 excludes all gastric secretions from the interior of the gastrointestinal sleeve device to separate ingested food and liquids in the sleeve device from all digestive secretions.
  • the gastroesophageal junction is one of the preferred attachment sites because the tissue wall is relatively thick at this location and it is relatively easy to access via a peroral route.
  • the area directly below the squamo-columnar junction (a zone of tissue that is considered to be at or slightly above the beginning of the GEJ 106) is currently thought to be the best place to attach a device, for example using T- tags, sutures or other fasteners.
  • a second aspect to the location of the attachment structure relates to the depth within the adjacent tissue wall (i.e., in a transverse direction to the longitudinal axis of the esophagus described above) within which the various anchors or retention structures disclosed herein reside. Applicants believe that the location in the transverse direction is subject to migration or other change post-implantation, as described in connection with Figures 13B through 13D.
  • FIG. 13B there is disclosed a highly simplified schematic cross sectional view of a tissue wall such as the wall of a hollow organ or lumen in the body, including the wall at the vicinity of the gastroesophageal junction.
  • the tissue wall comprises a serosa 170 and a muscularis 172. Additional tissue layers have been omitted for simplicity, hi general, as is appreciated by those of skill in the art, the serosa 170 is on the outside of or faces away from the stomach, and the muscularis is on the inside, or faces towards the interior of the stomach.
  • the serosa 170 thus includes a serosal surface 174 which faces away from the interior of the stomach, and the muscularis 172 includes a muscularis surface 176 which faces towards the interior of the stomach.
  • an attachment device or anchor 178 is illustrated in part in Figures 13B through 13D.
  • the attachment device 178 can take any of a variety of forms, described elsewhere herein.
  • the attachment device 178 includes a retention element 180 having at least one retention surface 182 thereon.
  • the retention clement 180 may be integrally formed with or attached to a tension element 184, which extends through the tissue wall and is secured to the device implanted within the gastrointestinal tract.
  • attachment mechanisms disclosed herein will be defined primarily in the context of an obesity device, which is attached in the vicinity of the GEJ 106, those of skill in the art will appreciate that the attachment system disclosed herein may be utilized in any of a wide variety of other anatomical locations, such as in the bronchial tubes, urethra, ureters, fallopian tubes, throughout the GI tract, and others which share a serosa or serosa like layer, such as in the kidney, bladder, and other organs, as would be recognized by those skilled in the art.
  • Retention surface 182 may " comprise any of a variety of forms, such as a proximal surface on a T-tag, proximal surface on a washer or disc, or any other surface which extends in a generally lateral direction with respect to a longitudinal axis of the tension element 184.
  • the transverse retention surface 182 may be radially enlargeable or expandable from a first;, reduced cross-sectional configuration to provide a low crossing profile such as for deployment through a deployment cannula, and a second, radially expanded or enlarged cross-sectional profile as illustrated in Figure 13B, to provide a retention surface 182 which will engage or interfere with tissue of the serosa 170 or muscularis 172 to resist proximal retraction of the attachment device 178 through the tissue. Transformation between the first configuration and second configuration can be accomplished in any of a variety of ways as is discussed further herein, such as by pivoting the retention element 180 about the attachment point to tension element 184, by radial expansion, by inflation, or other technique.
  • Tension element 184 may comprise any of a variety of connectors or elements adapted to extend through the tissue wall, such as a suture, or other single stand or multi-strand filament or material.
  • the tension element 184 is formed of a polymer such as PEEK or silicone.
  • the tension element 184 may also, in some embodiments, have elastic properties. In other embodiments the tension element 184 does not have elastic properties. By use of the term tension element, no specific mechanism is suggested, and the element is not required to be under mechanical tension.
  • the attachment device otherwise sometimes referred to herein as a tissue anchor, T-tag or other label, it is illustrated in Figure 13B in a schematic fashion as it may appear at the time of implantation. Since in certain implementations of the invention the length of the tension element 184 will exceed the uncompressed thickness of the adjacent tissue wall, the retention surface 182 may even be spaced slightly apart from the serosal surface 174 depending upon the transient motion or configuration of the stomach at any given time.
  • Applicants believe that the presence of the attachment device may cause or accelerate the formation of a layer 186 of serosal tissue having increased tissue density relative to unaffected or normal serosal tissue.
  • the layer of increased density 186 may result from a process in which the transverse retention surface 182 places pressure against the serosa 170, causing a localized necrosis due to the restriction of capillary blood flow. The necrosed tissue thereafter fibroses, as a part of a normal healing response.
  • the layer of increased density 186 or fibrosis may also result from a foreign body reaction triggered by the presence of the transverse retention surface 182. Applicants have observed a greater degree of fibrosis or denser tissue on the side of the T-tag facing the lumen of the stomach, for example on the retention surface 182.
  • the retention element 180 may relatively easily pass through the muscularis 172 and failure will result.
  • Suitable active agents may include any of a variety of growth factors, and/or chemical sclerosing agents which are well known for other medical applications.
  • the surfaces of the retention element and tension element may also be provided with an antibacterial characteristic, such as by eluting an antibiotic agent, or having a bacteriostatic or bacteria inhibiting coating. Drug eluting coatings are well understood in the coronary stenting arts, and can be adapted for use in the present context by those of skill in the art.
  • Active agents may be applied as a coating to the retention surface 182 or retention element 180, or may be impregnated into the material of retention element 180 and/or tension element 184, such as to permit a timed release into adjacent tissue. Incorporation may be accomplished by loading the active agent into tortuous pathways or pores exposed to the surface of the retention element 180, or by inclusion in a bioabsorbable or bioerodable carrier attached to or positioned in the vicinity of the retention surface 182. Energy sources may also be utilized, such as to generate heat or otherwise stimulate formation of a f ⁇ brotic response, as is discussed further below. Formation of the fibrotic layer 186 may also be facilitated by mechanical means, for example, in one embodiment, by roughening the retention surface 182 with the addition of fibrotic layer enhancement structures such as a plurality of bumps or etched lines.
  • FIG. 13E shows an implanted gastrointestinal stimulation system 2001 including a sleeve 2000 attached by an attachment cuff 214 with the use of T-tags 207. Also shown schematically is stimulator base housing 6 operably attached to cuff 214, as well as conductive element 10 and electrodes 12 as previously described.
  • FIG. 13F is an enlarged view of the attachment cuff 214 attached with T-tags 207 showing the transverse retention elements 209 of the T-tags 207 embedded in the stomach wall, as may be observed several weeks post implantation. Elements of the stimulator are not shown in FIG. 13F for clarity.
  • T-tag type fasteners can be used endoscopically to attach many of the structures described herein.
  • a T-tag is basically a retention element 180 in the form of a cross member or "T” that is attached to a tension element 184 in the form of an elongated member or tail at or near the mid-point of the T.
  • a “stem” may be a structure at the joining point of the T and tail. From the perspective of a peroral attachment technique, in which the attachment devices are preferably advanced through muscularis 172 in the direction of the serosa 170, the stem or tension element will be referred to herein as relatively proximal to the cross member on the T-tag.
  • the T-tag is a member of a more general family of tissue anchors, in which a proximally facing surface 182 (such as the proximal surface of the cross member) is adapted to be bent, folded, or otherwise reduced in crossing profile to a first configuration in which it can be advanced distally through a relatively small tissue opening, to a second configuration in which it presents a proximal serosal surface contacting area for resisting proximal retraction through the access pathway.
  • a proximally facing surface 182 such as the proximal surface of the cross member
  • the present invention relates more broadly to tissue anchors of the type for presenting a retention surface which may have any of a wide variety of configurations. Some are described in additional detail below.
  • the stem may also be referred to herein as a tension member, and may comprise a suture, or other single strand or multi-strand element for drawing the tissue anchor against the serosal tissue and/or connecting the tissue anchor to the implantable cuff or other endolumenal implant.
  • JOlIl] T-tag fasteners are generally configured to flex or pivot at the juncture of the T and tail to allow delivery along the axis of the T through a minimal puncture diameter.
  • T-tag fasteners can be configured with an extended tail that may extend out the mouth and optionally be used to parachute devices for attachment into position in vivo.
  • Other T-tag configurations can include, crimp, snap, screw or other means of securing the T-tag tail when appropriate.
  • T-tag fastener could include a dual tail.
  • a dual tail could be combined with extended tails that could then be tied out side the body with the ensuing knots then tightened within the body.
  • Such a dual tail could be constructed of one of a number of non-biodegradable suture materials known in the art including polypropylene, nylon, braided Dacron or silk. In some clinical situations biodegradable tails could be indicated and could be constructed using materials described herein. In a preferred embodiment the tails could be constructed of a monofilament material.
  • the retention surface 182 it may be desirable to increase the effective surface area of the retention surface 182. This may be accomplished using any of a variety of disc or button shaped attachment devices 178 disclosed herein, or by introducing a buttressing component or element in the nature of a washer or other structure for enlarging the effective surface area.
  • This buttressing structure may sometimes be referred to herein as a pledget.
  • the buttressing material is generally configured perpendicular to the axis of the tension element 184 (e.g. suture, rivet or staple) and therefore best distributes forces along the axis of the attachment means.
  • T-tags or other serosal anchors can be delivered through a hollow needle type delivery system (e.g. T-ANCHOR INTRODUCER GUN (Moss, Moss Tubes)) that has been redesigned/modified so it can be passed through the working channel of an endoscope.
  • a T-tag can be provided with an elongated tail that can extent out through the mouth and be used to parachute structures into place in-vivo.
  • the T-tags are placed such that the sutures of the T- tags could be knotted outside of the body and the knots could be pushed down the working channel or outside of the working channel of the scope until positioned to retain the cuff.
  • the suture tails could subsequently be removed.
  • two T-tags could first be placed to secure the cuff followed by placement of the rest of the T-tags.
  • the T-tag tension elements such as tails, sutures, or other structures as described herein, would terminate in the stomach, such as by tied knots, sliding buttons, or preexisting terminated ends, such that they would not need to be brought outside of the body.
  • any of a variety of suture locks may be utilized to secure the suture with respect to the cuff.
  • a suture lock is provided with a central aperture for moveably receiving the suture therethrough.
  • the lock may be configured for one way advance along the suture, having a spring biased engaging element for resisting movement of the lock in the opposite direction.
  • a central plug may be advanced into the central lumen, to compress the suture within the suture lock and retain the suture lock at a selected position.
  • Any of a variety of clips may also be axially or radially moved into position, to engage the lock with the suture.
  • the suture lock may be advanced down the suture and positioned with the desired tension against the interior surface of the cuff, and activated as necessary to lock the suture lock in place. The remaining suture tail may be severed, using conventional endoscopic techniques.
  • the suture lock may be secured to the cuff 102 such as at an aperture of the cuff, prior to implantation of the cuff 102 in the patient.
  • serosal anchors described herein can be formed using a single piece of Polypropylene, Nylon, PEEK, silicone, or. other polymeric material well known in the art for use in construction sutures, which forms the "T" and tail as a single unit.
  • two different materials can be combined, for example by insert molding, to achieve different properties of the "T” and tail.
  • this could be combined with a "T” portion that is coated with a material selected for specific clinical properties such as encouraging or discouraging either in-growth or adhesion.
  • the "T" portion may also be surrounded by another material such as ePTFE or Dacron graft material.
  • FIGS. 14A & 14B illustrate a curved T-member 300 for a T-tag fastener.
  • the convex curved tissue-contacting surface 302 of the curved T-member 300 serves to distribute the attachment force for an implanted device smoothly across the tissue to minimize any stress concentrations or higher pressure spots that could cause tissue necrosis and/or erosion.
  • the T member 300 has a double eyelet 304 for attachment of a suture or other filament.
  • the T-member is preferably molded of a fairly rigid, high strength biocompatible polymer such as PEEK.
  • FIGS 15A-15B illustrate a T-tag fastener 2200 with a hydrogel disc 2204 that can be placed between the deployed T-member 2208 and the extragastric (serosal) surface.
  • the disc 2204 could be delivered through the T-tag delivery needle, and unroll after passage through the needle.
  • the hydrogel disc 2204 acts as a buttress or pledget to distribute the forces transmitted between the T-member 2208 and the extragastric surface and thereby it strengthens the attachment of the T-tag fastener 2200.
  • the hydrogel used in FIGS. 15A-15B can optionally be replaced with alternate materials described herein for example silicone, NiTi and fluoropolymers.
  • a Hydrogel or other buttress or Teflon pledget for a T-tag could also deploy in some other manner.
  • the disc configuration shown can be replaced with for example, braided or woven wires or filaments that would expand/deploy after passage through the needle (FIGS. 16A-16B), a Malecot-style deployable tubular structure (FIGS. 17A-17B) or other expandable or deployable configuration (e.g. FIGS. 18A- 18B).
  • FIGS 15A-15B, 16A-16B, 17A-17B, and 18A-18B illustrate T-tag fasteners, such as 2200 in FIGS 15A-15B used with T-members 2208, uses of the T-tag fasteners without T-members and just with the hydrogel disc 2204 of FIGS. 15A-15B or the woven filaments, Malecot- style tubular structure, or the expandable structure of FIGS 16A-16B, 17A-17B, and 18A- 18B, respectively, are also contemplated.
  • a T-tag or T-pledget could have a discrete layer of a fabric interspersed between the T-tag and the serosal surface. This can advantageously facilitate tissue ingrowth and/or enhance transmural fastening of the device.
  • the fabric may be woven or non-woven.
  • the fabric may be permeable or impermeable.
  • the fabric material may be one or more of: Dacron, Dulex Mesh (Bard), Dual Mesh (Gore), PTFE (Teflon), ePTFE, plastics such as polyvinyl chloride, polyurethanes, polypropylene, polyesters, silicons, fibrin glues, extracellular collagen matrix materials such as Veritas (from Synovis) or Durgen Plus (from Integra), Goretex (Gore), silver composites, silver alloys, or any other suitable material referenced in the present disclosure. Any of the above materials can be impregnated or coated with a silver compound such as silver nitrate or silver oxide depending on the desired clinical result.
  • a silver compound such as silver nitrate or silver oxide depending on the desired clinical result.
  • retention elements 920 are designed for expandability.
  • a T-tag or T-fastener can be used to provide knot free means to retain a suture against pull through of an associated anatomic structure.
  • a further advantage of a T-tag is that the forces applied to the suture tail of the "T" are distributed over a larger area than a single stitch. This is accomplished by using a "T" dimensioned with a width wider than the diameter of the suture and a length longer than a typical bite or stitch.
  • a disadvantage of a T- tag is that insertion of a T-tag through tissue potentially requires a hole many times, for example 5-15 times, the diameter of the suture tail.
  • FIGS. 19C and 19D show how a T-pledget 920 or T-tag of woven cylindrical meshes that may be compressed or elongated to achieve a reduced diameter and expanded or shortened to become wider.
  • alternate configurations of a rolled and unrolled sheet can achieve a T-pledget 920 or T-tag with increased projected width relative to its rolled diameter through the use of matching cutouts, as shown in FIGS. 19A and 19B.
  • a "T" that is in a circular shape.
  • metals for example Ti, SS or NiTi.
  • encapsulating or coating the metal with a fluoropolymer or other coatings as described herein may also be beneficial.
  • T-tag with inflammatory reaction or other additives The pledget material could be optionally coated or impregnated with materials and/or medicaments as described herein.
  • the pledget can be coated with a material that would enhance inflammation and scar formation.
  • a coating or medicament that would either encourage or discourage in-growth can be applied.
  • a fastener that induces an inflammatory response for long term strength also include means to support the tissue during the weakened stage.
  • Inflammatory reaction materials would be limited to a portion of the T-tag or T-pledget as the inflammatory response weakens tissue before the scarring fibrosis occurs. Therefore, for example, having the area at the center of the T or pledget with this inflammatory material and the ends of the "T" without this material could have an optimized balance of short term and long term strength.
  • Drug-eluting coatings may be used to encourage or discourage tissue ingrowth into the fasteners or other device attachment mechanisms described herein. A low inflammatory response is generally desirable for encouraging tissue ingrowth.
  • Antiinflammatory drugs that may be used include steroidal anti-inflammatory drugs, e.g. prednisone, and nonsteroidal anti-inflammatory drugs (NSAID), e.g. chromalin.
  • drugs that may be used to control or reduce tissue ingrowth include Taxol (paclitaxel) (Bristol-Myers Squibb) and Sirolimus (rapamycin) (Wyeth-Ayerst Laboratories).
  • Embodiments designed for improved erosion resistance The purpose of the "T” or other retention element is to distribute and resist the forces that could act to pull it through tissue, in this case the gastric wall. To better achieve this result the "T” should resist excessive bending. Though a T-fastener is generally held parallel to the surface of the extragastric wall, at the ends of the "T” the gastric wall extends outward from the plane of the surface and the axis of the "T". In this case, the gastric wall could be at a 90-degree angle, or greater, to the ends of the "T”.
  • the "T” near the stem could be of a material of a durometer such as Shore 65D or higher and the material may change as one moves out along the arms of the "T” transitioning through 55D/100A to 9OA durometer or lower. Rounding, smoothing and structures that otherwise distribute forces over a larger area will also serve to reduce erosion at the ends of the "T".
  • a circular shaped "T" may be particularly desirable to reduce erosion.
  • the base stimulator housing 6 could be positioned on the serosal surface of the esophagus, GEJ, stomach, or intestine while the conductive element is wired through to the mucosal luminal side of the wall.
  • a system includes an endolumenal bypass sleeve as described herein in combination with any of the stand-alone electrical stimulation (pacing) devices known in the art.
  • pacing stand-alone electrical stimulation
  • Conventional electrostimulation devices may be used in the practice of this invention.
  • Such devices include, for example, those described in U.S. Pat. No. 5,423,872 (Jun. 3, 1995) (an implantable gastric electrical stimulator at the antrum area of the stomach which generates sequential electrical pulses to stimulate the entire stomach, thereby artificially altering the natural gastric motility to prevent emptying or to slow down food transit through the stomach); U.S. Pat. No. 5,690,691 (Nov.
  • Such a dual-therapy system could be advantageous as a sleeve could be initially implanted to accelerate weight loss, while the pacer/stimulator could be retained for maintenance.
  • the sleeve and stimulator could be both implanted in a first procedure. Once a desired clinical endpoint is reached, one of the sleeve or stimulator can be removed in a second procedure, while the other of the sleeve or stimulator retained within the body.
  • the sleeve and stimulator are implanted in separate procedures.

Abstract

Methods and devices for gastrointestinal stimulation are disclosed. In one embodiment, disclosed is an electrical stimulator device (3) that includes a circuit board (4) and a battery (2) contained within a base housing (6); a conduction element (10); and at least one electrode (12). In some embodiments, the stimulator base housing (6) can be directly attached to a wall of a body lumen. In other embodiments, the stimulator base housing (6) can be attached to a cuff (102) or a sleeve device (100). In still other embodiments, one or more elements of the system (92) are free-floating within the GI tract. The devices can be delivered endoscopically, and in some embodiments toposcopically.

Description

METHODS AND DEVICES FOR GASTROINTESTINAL STIMULATION
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/794,772, filed April 25, 2006 which is herein expressly incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION Field of the Invention
[0002] The invention relates generally to stimulation of the gastrointestinal tract with implanted electrodes.
Description of the Related Art
[0003] Gastrointestinal sleeve devices for treatment of obesity have been described in prior applications, as have various devices and methods for attachment of a gastrointestinal sleeve device within a patient's digestive tract. The present invention is directed to methods and devices for implantation of at least one electrode within the gastrointestinal tract, to deliver electrical stimulation.
SUMMARY OF THE INVENTION
[0004] In one embodiment of the invention, disclosed herein is a gastrointestinal stimulation system, that includes a gastrointestinal bypass sleeve and an electrical stimulator component. In some embodiments, the electrical stimulator component is attached to the sleeve. The system can also include a gastrointestinal attachment cuff having a tubular body, a proximal end and a distal end. The electrical stimulator component can include a circuit board and a battery; a conductive element; and at least one electrode.
[0005] In some embodiments, the stimulator component includes at least about two, three, four, five, or more electrodes. A first and a second electrode can be spaced at least about lcm, 2cm, 3cm, 4cm, 5cm, 10cm, 15cm, 20cm, or more apart in some embodiments. In other embodiments, a first and a second electrode can be spaced apart between about l-20cm, 2- 10cm, 3-8cm, or 3-5cm. In some embodiments, the battery is configured to be recharged using RF energy.
[0006] The conductive element can be a ribbon. The ribbon can have a U-shaped, S-shaped, or linear cross-section. The circuit board and battery can be hermetically sealed in a base housing. The base housing can be attached to the outer diameter of the sleeve, or the inner diameter of the sleeve. The electrical stimulator can be triggered by a sensor configured to detect pressure, temperature, pH, motion, and/or strain. The electrode can be annular band- shaped. In some embodiments, the conductive element is a lead wire. In some embodiments, the system includes at least one biasing element operably connected to an electrode. The biasing element can be configured to increase one of the contact surface area or the contact surface time between the electrode and a lumen of the gastrointestinal tract. In some embodiments, the biasing element is configured to increase the contact surface area between the electrode and a lumen of the gastrointestinal tract. In some embodiments, the biasing element is a continuous helical band. In other embodiments, the biasing element is a ring. Alternatively, the biasing element can be a flexible tube, and the electrode is positioned on an outer surface of the tube. In some embodiments, the gastrointestinal bypass sleeve is at least partially inverted within itself, and adapted for eversion within the gastrointestinal tract.
[0007] Also disclosed herein is a gastrointestinal stimulation system that includes a electrical stimulator component, the stimulator component comprising a circuit board and a power source contained within a base housing; a conductive element; and at least one electrode; wherein the stimulator component is configured to be transmurally attached with a plurality of tissue anchors to a wall of the gastrointestinal tract.
[0008] Also disclosed herein is a method of treating a patient, including the steps of providing an electrical stimulator component, the stimulator component comprising a circuit board and a power source contained within a base housing; a conductive element; and at least one electrode; positioning the base housing of the electrical stimulator component in the patient's digestive tract such that the base housing is positioned in the vicinity of the gastroesophageal junction; securing the base housing to a structure in the vicinity of the gastroesophageal junction, positioning the electrode within the intestine such that the electrode contacts the wall of the intestinal lumen; and stimulating the intestinal lumen. The securing step can include advancing at least one, two, three, four, or more tissue anchors through the tissue wall and positioning a retention surface on each tissue anchor in contact with the serosal surface.
[000,9] Also disclosed herein is a method of treating a patient, including the steps of providing a gastrointestinal sleeve device having an elongate tubular body, with a proximal end and a distal end; providing an electrical stimulation component comprising: a circuit board and a battery contained within a base housing; a conduction element; and at least one electrode operably attached to the sleeve device; positioning the gastrointestinal sleeve device in the patient's digestive tract such that the proximal end of the tubular body is positioned in the vicinity of the gastroesophageal junction to receive ingested material from the patient's esophagus and the distal end of the tubular body is positioned in the patient's intestine; positioning the base housing in the vicinity of the gastroesophageal junction; securing the proximal end of the sleeve device and the base housing of the electrical stimulator component in the vicinity of the gastroesophageal junction; securing the base housing of the sleeve device in the vicinity of the gastroesophageal junction, and everting the sleeve to position the distal end and the electrode within the intestine.
10010] In addition, disclosed is a method of treating a patient, including the steps of providing a gastrointestinal sleeve device having an elongate tubular body, with a proximal end and a distal end; providing an electrical stimulation component comprising: a circuit board and a battery contained within a base housing; a conduction element; and at least one electrode; positioning the gastrointestinal sleeve device in the patient's digestive tract; positioning the base housing in the patient's gastrointestinal tract; and treating a patient using both the bypass sleeve and the electrical stimulator device. The base housing can be operably attached to the sleeve. In some embodiments, positioning of the electrical stimulation device and the gastrointestinal sleeve device does not occur during the same procedure. The method can also include the steps of providing a gastric space-filling device operably attached to the base housing of the electrical stimulation component; and deploying the space-filling device within the stomach. In some embodiments, the space-filling device is a balloon, solid implant, or a bezoar. BRIEF DESCRIPTION OF THE FIGURES
JOOIl] FIG. 1 schematically illustrates one embodiment of a gastrointestinal stimulation system that includes a cuff, sleeve, and electrical stimulation component including a plurality of annular band electrodes.
[0012] FIG. 2 schematically illustrates an embodiment of a gastrointestinal stimulation system that includes biasing elements in the form of rings, to increase contact surface area and/or time of electrodes to the intestinal lumen.
[0013] FIG. 3 schematically illustrates an embodiment of a gastrointestinal stimulation system that includes biasing elements in the form of a helical band, to increase contact surface area and/or time of electrodes to the intestinal lumen.
10014] FIG. 4 schematically illustrates an embodiment of a sleeveless gastrointestinal stimulation system.
[0015] FIG. 5 schematically illustrates an attachment mechanism for a gastrointestinal stimulation system, in one embodiment of the invention.
[0016] FIGS. 6-8A schematically illustrate cross-sections of various embodiments of ribbon electrodes, according to some embodiments of the invention.
[0017] FIG. 9A schematically illustrates a cuff-less, sleeveless gastrointestinal stimulation system where the base stimulator is directly attached to a wall of the GI tract, according to one embodiment of the invention.
[0018] FIG. 9B schematically illustrates a gastrointestinal stimulation system where the base stimulator is attached to a gastric balloon, according to one embodiment of the invention.
[0019] FIGS. lOA-C schematically illustrate steps showing toposcopic delivery of a gastrointestinal stimulation system, according to one embodiment of the invention.
[0020] FIG. 11 schematically illustrates a system for pressurizing a toposcopically deliverable sleeve, according to one embodiment of the invention.
[0021] FIGS. 12A-B illustrate a toposcopic deployment system that can be used to deliver a gastrointestinal stimulation system, according to some embodiments of the invention. [00221 FIG. 13 A illustrates a possible attachment site for a gastrointestinal stimulation system, according to some embodiments of the inventions.
[0023] FIGS. 13B-13D illustrate a possible model of tissue ingrowth following transmural T-tag implantation, according to some embodiments of the invention.
[00241 FIGS. 13E-19D illustrate attachment mechanisms, including T-tags and T- pledgets that can be used for a gastrointestinal stimulation system, according to some embodiments of the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT [0025J The present invention provides methods and devices for implantation of at least one electrode within a body lumen, which may be the gastrointestinal tract, to deliver electrical stimulation. The electrodes may be supported by an endolumenal bypass sleeve, or by an attachment cuff, as have been described in United States Patent Application Serial No. 10/698,148, filed 10/31/03, published 5/13/04 as U.S. Patent Pub. No. 2004-0092892 Al and entitled "APPARATUS AND METHODS FOR TREATMENT OF MORBID OBESITY" (and may be referred to herein as the "Kagan ' 148 Application"); United States Patent Application Serial No. 11/025,364, filed 12/29/04, published 8/11/05 as U.S. Patent Pub. No. 2005-0177181 Al and entitled "DEVICES AND METHODS FOR TREATING MORBID OBESITY" (and may be referred to herein as the "Kagan '181 Application"); United States Patent Application Serial No. 11/124,634, filed 05/05/2005, published 01/26/06 as U.S. Patent Pub. No. 2006-0020247 Al and entitled "DEVICES AND METHODS FOR ATTACHMENT OF AN ENDOLUMENAL GASTROINTESTINAL IMPLANT" (and may be referred to herein as the "Kagan '634 Application"); United States Patent Application Serial No. 11/400,724, filed 04/7/2006, published 01/11/07 as U.S. Patent Pub. No. 2007-0010794 Al and entitled "DEVICES AND METHODS FOR ENDOLUMENAL GASTROINTESTINAL BYPASS" (and may be referred to herein as the "Darin '724 Application"); and United States Patent Application Serial No. 1 1/548,605, filed 10/11/2006, entitled "DEVICES AND METHODS FOR ENDOLUMENAL GASTROINTESTINAL BYPASS" (and may be referred to herein as the "Dann '605 Application") the disclosures of which are incorporated by reference in their entireties herein. As will be apparent from the descriptions below, in some embodiments, the electrodes may alternatively be attached to nontubular support structures such as an elongate flexible ribbon or tether, which is in turn attached to the wall of the GI system using the transmural anchoring techniques disclosed in the above referenced patent applications. Alternatively, the structure could be held in place via non-transmural devices that resist the natural tendency of the GI tract to expel devices from the system. Examples of suitable non- transmural devices include gastric balloons and bezoars or other devices large enough to resist passage through the pylorus or out through the esophagus once implanted in the stomach. Other devices include stent like structures placed either in the esophagus or the stomach that may hold the stimulator in place through apposition of the structure to the stomach or luminal wall. These devices could also be placed inside or past the pylorus.
Cuff and/or Sleeve System with Stimulation
[0026] The method and devices used for attaching a cuff and/or sleeve as disclosed in the aforementioned patent applications could further incorporate an electrical stimulation component as part of the sleeve, or just attached to the cuff in some embodiments. A gastrointestinal (GI) stimulation device, in some embodiments, preferably includes a power source, such as a battery, and is used to deliver energy to any portion of the GI tract, such as a lumen. In some embodiments, the energy is preferably not delivered to the stomach even though the device may be attached in the stomach or the gastro-esophageal junction.
[0027] The device is intended to treat obesity, any of the co-morbidities associated with obesity including diabetes; GI inflammatory diseases (e.g., Crohn's disease, ulcerative colitis, celiac sprue), GI hypermotility and well as hypomotility disorders (e.g., gastroparesis, ileus, bowel obstructions, achalasia, irritable bowel syndrome, Hirschprung's disease, toxic megacolon, Ogilvie's syndrome), malabsorptive disorders, and any other disease with manifestations involving the GI tract.
[0028] The electrodes would preferably stimulate the lumen distal to the stomach. They could be placed in the pylorus, duodenum, ileum, jejunum, colon or any combination of these sections of the GI tract. In other embodiments, the electrodes could stimulate the lumen of the stomach or esophagus. In still other embodiments, the electrodes could stimulate the lumen of the biliary tree, such as the common bile duct, cystic duct, hepatic duct, or pancreatic duct; or other structures such as the sphincter of Oddi.
[0029] Not to be restricted by theory, the stimulation could be used to reduce the feeling of hunger or it could increase or decrease the rate of peristalsis to increase or decrease the rate at which food passes or it may act to accelerate or inhibit absorption of digested material by increasing or reducing the activity of the active transport mechanisms in the intestinal wall.
Triggering
[00301 The stimulator could operate on a constant program, variable program, or a sensor that detects the intake of food and/or liquid could trigger a stimulation program. If it is triggered by a sensor detecting intake of foods and/or liquid it could be preset to run for a specific period of time following that triggering mechanism.
[0031} Variables that could be detected by the sensor include pressure, temperature, motion, strain or pH to indicate the intake of food or liquid.
Stimulator Device Description
[0032] In one preferred embodiment, the electrical stimulator would include a power source, a circuit board, a conductive element, and at least one electrode configured to transmit the energy to the lumen. The power source is most preferably a battery. The circuit board is most preferably a printed circuit board, although wire-wrapped or point-to-point constructed circuits could also be used. The battery and printed circuit board could be, in some embodiments, part of the cuff or part of the sleeve. If the battery and circuit board are part of the sleeve, they could be near the intake end of the sleeve or alternatively could be placed at a distance from the intake end, such as past the pylorus, to help reduce any direct weight on the anchor points or cuff/sleeve attachment.
[0033] The circuit board and power source are most preferably hermetically sealed together in an electrical stimulator base housing. One way to seal the housing of the device would be to encase it in a metal foil. The printed circuit board would preferably generate an oscillating circuit that would be used to drive the stimulator. The voltage, pulsewidth, frequency and duty cycle can be programmable, or they could be preprogrammed before implantation.
[0034] In some embodiments, the electrical stimulator preferably has a preset operating frequency and period which can vary according to the alteration of stomach motility to be obtained and/or to the pathological condition of the patient. Generally, the electrical stimulator has an operating frequency of about 2 to about 30 pulses per minute. Preferably, the process of this invention employs stimulation of the small intestines at a rate of about 2 to about 30 pulses/minute with each pulse lasting about 0.1 to about 4 seconds such that there is a pause of about 3 to about 30 seconds between the pulses. The electrical discharge of each pulse can vary from approximately 1 to 15 volts for voltage-controlled stimulation and from 2 to 15 milliamperes for constant current stimulation. More preferably, the pulse rate is about 12 to about 14 pulses/minute with each pulse lasting about 0.1 to about 0.5 seconds with a pause of about 4.5 to about 5 seconds between pulses. Preferably, the pulse amplitude is about 0.5 to about 15 milliamps. More preferable, each pulse consists of a train of micro-bursts with a frequency of about 5 to about 100 Hz.
[0035] The stimulator base housing would preferably be placed on the outside diameter of the sleeve so it would not interfere with food passing through the sleeve, however it could also be sealed between layers of the sleeve material. This may help further protect the stimulator from any exposure to stomach acid or other material.
[0036] Figure 1 illustrates a gastrointestinal stimulation system 1 that includes a gastrointestinal sleeve device 100 attached to an artificial attachment cuff or stoma device 102 implanted within a patient's stomach 104. The attachment cuff 102 can be implanted in the vicinity of the gastroesophageal junction 106, or at the outlet of a surgically created gastric pouch (not illustrated). The attachment cuff 102 preferably does not restrict the flow of food, although it may be provided with a restrictive opening if desired. The cuff 102 can have a fixed diameter opening 108 equal to, larger or smaller than the fully open diameter at the native GEJ. Alternatively, the cuff 102 can have an adjustable stoma opening or it can be a "smart" stoma that adjusts the size of the stoma opening in response to various conditions.
[0037] The attachment cuff 102 is preferably configured for peroral delivery and attachment using endoscopic techniques. Alternatively, the cuff 102 can be implanted using laparoscopic or open surgical techniques. Additional details of the cuff, stoma and attachment can be found, for example, in any of the related applications incorporated by reference herein, such as, for example, the Dann '605 application.
|0038] The stimulation system 1 shown in Figure 1 also includes an electrical stimulation component 3 including a battery 2 and circuit board 4 preferably hermetically sealed within in a base housing 6. As illustrated, the base of the stimulation component 6 is shown closer to the greater curve 7 of the stomach 104. The base housing 6 of the device 3 may be placed at any location on the circumference of the sleeve 100 and there may be advantages to being placed on the lesser curve 8 side of the circumference, or any other aspect of the sleeve 100. In addition the stimulator base 6 could be attached to the sleeve at some distance farther away from the cuff 102 than depicted in the drawing, e.g., at least about 25cm, 50cm, 75cm, 100cm, 125cm, or more.
[00391 The electrical stimulation component 3 preferably also includes a conductive element 10, which can be a lead wire in some embodiments, and that, as depicted in FIG. 1, could be a bundle of multiple wires to individually power one or more electrodes 12. Alternatively, there could be more than one electrode 12 per wire 10. The optimal configuration would be driven by the desired stimulation program. The electrodes 12 shown in FIG. 1 can be in the shape of an annular band that can partially or fully circumscribe a portion of the sleeve 100. However, various other sized and shaped electrodes are contemplated as well. Alternatively, the electrodes could be connected wirelessly to the stimulator. One of ordinary skill in the art would be able to select an appropriate method for wireless stimulation of an electrode, such as, for example, as described in U.S. Patent Publication No. 2006-0085042 to Hastings et al., hereby incorporated by reference in its entirety. This technology could be advantageous because it could allow a stimulator to be placed in traditional surgical implantation techniques or worn external to the body while the electrodes reside in the lumen of the GI tract.
[00401 The battery 2 for the stimulation component 3 could be relatively small, as the sleeve 100 is not necessarily designed as a permanent implant, although permanent implants are also contemplated. One example of a stimulation component's specified energy and lifespan of the device with a battery is described below. Battery/Power Example:
|0041 J The formula to calculate the energy delivered during a stimulation cycle is:
(0042| Energy = (Voltage2/Resi stance) * Pulsewidth * Frequency of Stimulation * Duty Cycle
|0043J Given sample parameters of one embodiment:
100441 Voltage = 5 Volts; Resistance = 350 Ohms; Pulsewidth = 200 microseconds; Frequency = 40 Hz; Duty Cycle = 40% (2 sec. on and 3 sec. off), the energy delivered for one cycle would be 228 microwatts. Using the formula to determine current:
{0045! I (current) = Power/Voltage = 228 microwatts/5 Volts = 45 micro amps
(0046] In one embodiment, if a 90 milliampere battery 2 is selected for use for the stimulation element 3, then the lifetime of that battery 2 would be equal 2 x 106 seconds, or about 23 days. If a longer battery life is desired, a 135 milliampere battery would advantageously increase the battery lifetime by 50%. Batteries in this size would be approximately of that found in watches or calculators.
Electrodes
10047} The electrode(s) 12 of a stimulation component 3 would most preferably contact the inside wall of the lumen. This means some exposed part of the electrode 12 would need to be on the outside surface of the sleeve 100 or if there is no sleeve 100 exposed to the inner surface of the mucosal lining of the lumen. Contact with the lumen can be achieved with a variety of means. In a preferred embodiment, barbs or other forms of fixed attachment to the intestinal wall are not used as this could provide the intestines with a point to pull on the device 3 and cause complications such as an accordion-like response in the intestine, potentially resulting in intussception or volvulus, rupture of the intestinal wall, or detachment of the device's anchor mechanisms. Other embodiments disclosed herein illustrate various different non-limiting electrode shapes and configurations.
10048] The electrodes 12 will typically have sufficient contact with the luminal wall because of the natural tendency for the lumen to close down on whatever is in it. In some embodiments, there could be various biasing elements 16 incorporated into the sleeve that help bias the electrode 12 in a direction to improve the surface area and/or duration of contact. The shape of the electrodes 12 themselves could help induce better contact with the mucosal lining. The electrodes 12 could be a raised form such as pyramid, hemisphere or mushroom shaped to help create better contact. While the electrodes 12 can be placed in contact with the luminal surface, in some embodiments one or more electrodes 12 can be placed on the serosal surface, or even some electrodes 12 in contact with the luminal surface while other electrodes 12 are in contact with the serosal surface.
[0049] A stimulation system can involve any number of electrodes 12 depending on the desired clinical result. In some embodiments, a stimulation system has at least about 1, 2, 3, 4, 5, 10, 15, 20, or more electrodes 12. Furthermore, the electrodes 12 can also be spaced apart any appropriate distance depending on the desired clinical result. In some embodiments, a first electrode may be spaced apart from a second electrode by between about l-20cm, preferably between about 2-1 Ocm, in some embodiments between about 3-8cm, in other embodiments between about 3 -5cm.
[0050] FIG. 2 illustrates a gastrointestinal stimulation system 14 similar to that of FIG. 1, and including one or more biasing elements 16. The biasing elements 16 as shown schematically in FIG. 2 is a series of one or more rings 16 biased towards an expanded state that are connected by a wire 10 to power the electrodes 12 that are on the rings 16. There could be one or more electrodes 12 on each ring 16. Using rings 16 as biasing elements 16 would be preferable when there is the desire to place multiple electrodes 12 at one circumferential area of the intestine 114.
[0051] FIG. 3 illustrates a gastrointestinal stimulation system 15 where the biasing element is a helical support structure 18 that runs part of or all of the length of the sleeve 100. The one or more electrodes 12 are most preferably attached to the helical support structure 18. One possible advantage of a helical support structure 18 that is biased towards an expanded state is that, unlike with the rings 16 shown in FIG. 2, there would not be a ring or oval shaped device for the peristaltic contraction to 'pull' on, if this is a factor to consider, as it would tend to collapse as necessary when compressed, but still maintain contact with the lumen. In other embodiments, any support structure of the sleeve 100 described in any of the prior applications incorporated by reference, such as the Dann '605 application, could also incorporate electrodes 12 in its design.
[0052] In some embodiments, a biasing element 16 could be made, at least in part, of a super elastic metal, such as Nitinol, other shape meory material, or could be made from plastic or could be a combination of both where the core is Nitinol and they are surrounded by or partially surrounded by a plastic. In this case the plastic could also serve as an insulator where desired.
Programming
[0053] The electrical stimulation component 3 could be pre-programmed before placement. There could be a separate programmer remote from the stimulator 3 that could control any of the aspects of the stimulation cycle and/or triggering mechanism of the device wirelessly from outside the patient. The stimulator with one preset program could be used initially. Then, after a certain time, a device with a different program could be switched out. This could occur when replacing the sleeve 100 if the stimulator component 3 is integrated with the sleeve 100. When the sleeve 100 is changed the stimulation program may be varied using the length of the sleeve 100 as a variable and what points of contact in the GI tract are expected to exist with the modified length of tubing. For example, the stimulator component 3 may deliver more energy if there is a shorter sleeve 100 and the stimulator component 3 could deliver less energy through each electrode 12 if there is a longer sleeve 100 or any such combination of these variables could be used.
Rechargeable Battery
[0054] In some embodiments, the battery 2 could be recharged wirelessly by an external power source that uses RF energy transmitted through the body to recharge the battery 2, such as transcutaneously. In other embodiments, a terminal is present on the cuff 102 that could be accessed trans-orally to recharge the battery through direct conduction. This could be done during routine follow up with a diagnostic endoscopic procedure to inspect the system in place. In yet other embodiments, the battery 2 could be a simple disposable battery that is configured to run out of charge at or near the time of a scheduled sleeve removal or replacement. One of ordinary skill in the art will appreciate that a wide variety of battery 2 types can be selected for use with the disclosed stimulation systems.
Stimulator Separate from Sleeve
[0055] The stimulator component 3 as described above could also be separate from the sleeve element 100 of the system. In some embodiments, a gastrointestinal stimulation system 40 does not include a sleeve element 100. This would allow for a variety of treatment options. The electrical stimulator base unit 6 could be attached to the cuff 102, such as tethered to the cuff 102, and the electrodes 12 could be on a ribbon 24 or other device that is advanced down the GI tract, as shown in FIG. 4.
Ribbon type electrode connector
[0056] The ribbon 24 that holds the electrodes 12 could have a shape that would help bias the electrodes 12 into contact with the lumen. A compliant ribbon 24 may have enough contact with the lumenal wall because of the tendency of the intestine 1 14 to collapse into a flat configuration.
[0057J However, it may be advantageous to have the ribbon 24 take on a predefined shape such as a helix through the use of reinforcement elements in the ribbon 24. In this configuration the electrodes 12 would be oriented to be on the outside of the helical surface of the ribbon 24. These could be stiffer plastic materials or super elastic metals such as JNitinol used to make the helical structure. The ribbon 24 itself may be of a material that could be shape set into this configuration.
[0058] The cross sectional profile of the ribbon 24 could be flat, U-shaped, S- shaped or some other complex form. Some non-limiting embodiments are illustrated in FIGS. 6-8. FIG. 6 illustrates a ribbon 50 with a U shaped cross-section. Ribbons preferably have first and second sides. Electrodes 12 are shown operably attached to the ribbon 50. One end of ribbon connects to the base unit 6 of the stimulation element. FIG. 7 illustrates a ribbon 52 with an S-shaped cross-section. Such an embodiment can have electrodes 12 on both first and second sides of the ribbon 52 as shown. The U shaped 50 or S shaped 52 cross sections as depicted in FIGS. 6-7, advantageously provide elevated areas where electrodes 12 could be placed that may have a higher likelihood of making contact with the lumen. FIG. 8 illustrates an embodiment where the ribbon 54 is substantially flat. Attached to ribbon 54 are electrodes 12 on both the first and second sides of the ribbon 54. In some embodiments, electrodes 12 may be only on either the first or second side of the ribbon 54. Arrows 51, 53, 55, 57 of FIGS. 6-8A, respectively, illustrate a direction in which an end of the ribbon 50, 52, 54 connect to base 6 of stimulator component 3.
{0059] FIG. 8A illustrates a ribbon 56 with operably connected electrodes 12 similar to that shown in FIG. 8A3 also having a lumen 58. Lumen 58 is preferably configured to allow a stiffening element (not shown) to pass therethrough in order to provide additional structural support for the ribbon 56. In some embodiments, the stiffening element is a guidewire. The guidewire may have a shape memory material such as Nitinol to allow for possible adjustment should a change in the degree of stiffening be required. Any of the sleeves, such as sleeve 100 disclosed herein can also have one or more lumens (in addition to the artificial stoma for bypass of food contents, etc.) present that are configured to receive a stiffening element.
[0060] In some embodiments, the ribbon 24 can have a protrusion, bulge, or balloon (not shown) in its construction on or near the distal end to help transfer a desired amount of force from the peristaltic contractions to help keep the ribbon 24 in place.
(0061] FIG. 5 shows one embodiment of a fastener 660 comprising a hanger 661 that also functions to hold two layers of folded tissue together. The fastener 660 may be used to secure the base unit 6 of the stimulation component 3 to the mucosal wall. Many other suitable fasteners are disclosed, for example, in the Kagan '634 application. The fastener 660 of FIG. 5 has a toggle 662 that pivots on a hinge 663 so that is can be aligned with the post 664 as it is passed through tissue layers, and can then be pivoted to hold the tissue layers together.
[0062] The toggle 662 helps to distribute forces that hold the fastener 660 in place over the length of the toggle 662, and also prevents the fastener 660 from being pulled through the hole. Alternative to the toggle 662, a similar functioning apparatus such as a disc or a multi-arm umbrella could also be used to distribute forces on the adjacent tissues while preventing the fastener 660 from passing through the hole. This fastener functions similarly to the T-tag fasteners described herein. Some of the attachment structures described herein such as that of FIG. 5 are illustrated in connection with tissue plications; however, these attachment structures may also be used transmurally, i.e., through one tissue layer.
Tubular electrode connector
[0063] In other embodiments, the electrodes 12 could be on the outside of a flexible tube (not shown). The tube could be hollow or solid as desired. The diameter of the tube would be ideally just large enough to allow good contact with the lumen of the intestine but not too large to cause any reaction in the intestine or risk occluding the intestine. If hollow, the ends of the tube would most preferably not be open to keep any food or material from impacting in the tube. A hollow or solid tube could have any of the structural elements as conceived for the sleeve as previously described, for example, spiral reinforcements, ribs, or a larger node near the distal end to help capture force from the peristaltic motion of the intestines. In some embodiments, the tube could have shape set into the lube itself during manufacturing to give it a preferred structure. The tube could form a helical structure to bias an outer surface of the helix into contact with the lumen. The center of the helical structure could be large enough to allow a cuff/sleeve system to be implanted through the center of it. In this way a sleeve could be initially implanted but then removed after a certain period of time and just the stimulator would remain. Alternatively, the stimulator could be removed and the sleeve could remain. In still other embodiments, one of the stimulator or the sleeve could be implanted first and then the other device could be added after a certain period of time
[0064] These various combinations would allow a wide range of treatment choices based on either how a patient responds to various the different elements of the system or could be used to stage the procedure to build the impact on weight loss. It could also be determined that the sleeve is beneficial for the early resolution of co-morbidities and/or initial weight loss and then after a certain period of time intestinal stimulation is enough to maintain the weight loss. Stimulator component attached without cuff or sleeve.
[0065] In some cases it may be desirable to attach the stimulator to the GEJ without a cuff or sleeve. One such stimulation system 90 is shown in FIG. 9A. In this case the stimulator could be attached directly to a subsection of the GEJ with transmural anchors as described in, for example, the Kagan '634 or Dann '605 applications. As shown in FIG. 9A, in one embodiment, an attachment or fastener device 651 for the base stimulator 6 can be driven through a single tissue layer, with attachment means 654 on the end of a post 653 positioned within the passageway, and a cone shaped spring positioned 652 on the serosal side. The embodiment shown in FIG. 9A is preferably configured so that its installation does not narrow the passageway of the organ. Delivery of fastener embodiments communicating with the exterior of a hollow organ as shown in FIG. 9A may incorporate means to control capture of other structures. Though it may be clinically desirable to capture other structures as in the case of capturing the diaphragm by fasteners placed in the cardia of the stomach it is more likely that this would be undesirable. Fastening means could incorporate shielding means and/or means to invaginate the organ wall as the fastener is advanced through the organ wall.
[0066] Also shown in FIG. 9A is a conductive element 24 operably attached to the base stimulator 6 at its proximal end, and having electrodes 12 operably attached to the conductive element 24 within the intestine more distally as shown. In some embodiments as shown, the conductive element 24 can be a ribbon as shown in FIG. 4. In another embodiment, the base stimulator 6 may be attached to the fastener illustrated in FIG. 5.
[0067J Alternatively, as illustrated in the system 92 of FIG. 9B, the base stimulator 6 could be on a device 60 configured to remain in place in the stomach 104 without transmural attachment of device 60 to the stomach 104. Space-occupying devices such as gastric balloons or bezoars are known to those in the art. These are devices that are designed to remain in the stomach after implantation. A stimulator base 6 as described could be attached to such a device 60 or inside the device 60 and the ribbon, tether, or the like holding the electrodes 12 in place would be attached either to the anchoring device 60 and/or the base stimulator 6 itself. In one configuration, there could be a cuff and/or sleeve device (sleeve shown as 12 in FIG. 9B) implanted after a gastric balloon 60 with a base stimulator 6 and conductive element is implanted. In this configuration, there would be a base stimulator 6 as described above and a series of intestinal electrodes 12 with the system not fixedly anchored to tissue. In the embodiment shown, electrodes 12 are preferably raised on top of a helically-biased tube 62 (which may be the conductive element 10, or could alternatively serve as a scaffolding for a lead wire in some embodiments) separate from, but wrapped around the outer diameter of the sleeve 100.
Subsection of the GEJ for attachment
[0068] In some embodiments, a preferred location to attach the base 6 of the stimulator component 3 is selected. For example, the side of the GEJ closest to the lesser curve of the stomach may have characteristics such as lesser motility or a different type of tissue that makes it better to attach the stimulator base 6.
[0069] Note that the part of the GEJ closest to the lesser curve of the stomach can be an ideal place to attach other devices in the stomach besides a stimulator. It could be an advantageous anchor point for volume occupying devices or other sensors to monitor physiologic parameters such as pH.
[0070] When the stimulator is attached directly to the GEJ without a cuff or sleeve the ribbon type electrode as described above could be used, or any other type of flexible connector for connecting the intestinal electrodes to the stimulator
Toposcopic Delivery
[0071] In some embodiments, a gastrointestinal stimulation system can be placed in a patient using a toposcopic delivery method, such as a method similar to that disclosed in the Dann '605 application. Other useful devices and methods for toposcopic access and delivery are disclosed in U.S. Provisional Patent Application No. 60/826,862 to Dann et al., filed on September 25, 2006 and hereby incorporated by reference in its entirety. Embodiments of gastrointestinal stimulation systems that are configured to be delivered toposcopically most preferably include electrodes operably attached to sleeve elements, such as, for example, the embodiments illustrated in FIGS. 2 and 3. However, toposcopic delivery of other embodiments, such as wireless electrodes, is also possible. [0072] In some embodiments of the present invention, as shown in FIGS. 10A- 1OC, toposcopic delivery of sleeve 100 with attached electrodes 12 is achieved by performing the following steps:
10073] Optionally attach cuff 102, if a cuff is part of the gastrointestinal stimulation system (not shown), as disclosed above, as well as, e.g., in the Dann '605 application. Base 6 of the stimulator component 3 can be held in a fixed position in a filling catheter 400, and later attached to the cuff 102 after complete eversion of the sleeve 100 in some embodiments. For simplicity, the attachment anchors for attaching cuff 102 to tissue in the vicinity of GEJ 106, as well as conductive element 10 of the electrical stimulator component 3 are not shown.
[0074] Place a filling catheter 400 in fluid communication with a flushing device 416 (FIG. 1 1).
[0075] Attach sleeve 100 that can include electrodes 12, biasing elements 16, base stimulator 6, and conductive element 10 (not shown) as described above, to filling catheter 400, invert sleeve 100 within the filling catheter, and create a fluid-tight seal 468 between the sleeve 100 and filling catheter 400, if these steps have not been previously done.
[0076] Use a sleeve grasper or advance filling catheter 400 to position distal sleeve end 154 of the undeployed sleeve 100 at or into the pylorus 116.
[0077] Flush filling catheter 400 with fluid to deploy sleeve 100, with attached electrodes 12 and optionally biasing elements 16, into intestine 114.
[0078] Confirm full placement using back pressure measurements or fluoroscopy or x-ray to detect radiopaque markers (not shown) on sleeve 100.
[0079] Attach cuff 102 (not shown) to sleeve 100.
[0080] FIG. 1OA shows the proximal end of sleeve 100 and the distal end of filling catheter 400 deployed in stomach 104, with distal end 112 of sleeve 100 including electrodes 12 attached to biasing elements 18, retracted proximally within the filling catheter 400 at least as far as the esophagus 164. Also shown is stimulator base 6. Conductive element is not shown in FIGS. lOA-lOC for clarity. FIG. 1OB shows sleeve 100 partially unraveled or otherwise deployed such that distal end 112 has advanced past GEJ 106. FIG. 1OC shows sleeve 100 including biasing element 18 and attached electrodes 12 fully deployed down intestine 114. In some embodiments, the conductive element 10 of the stimulation component 3 is operably attached to a wall of the sleeve 100 to help prevent kinking of the conductive element 10 during eversion at the time of toposcopic delivery. In another embodiment, the biasing element 18 could be placed in the sleeve 100 after toposcopic delivery. In this case, the electrodes 12 and conductive element 10 would be built into the wall of the sleeve 100 and could add very little stiffness to the construct to help facilitate toposcopic delivery. The sleeve 100 may have a lumen built into or attached to the wall of the sleeve 100 that runs underneath the electrodes 12. After toposcopic delivery, a biasing element 18 with a preformed shape could be inserted into the lumen and it would then help bias the electrodes 12 outwards towards the wall of the lumen. One example of this would be a helical lumen in the wall of the sleeve 100 underneath the electrodes 12. The biasing element 18 could be, in one embodiment, a nitinol wire shaped to form a helix. The temperature of the wire could be lowered before insertion to make the wire as flexible as possible. When the wire rewarms to the ambient temperature in the lumen it would re-form its biased shape.
[0081] Sleeve 100 can be inverted one or more times to create multiple layers of sleeve that unravel during toposcopic delivery. For example, a sleeve 100 can have two, three, four, or more inversions. In preferred embodiments, sleeve 100 is inverted once.
[0082] FIG. 11 illustrates a method of using a filling catheter to facilitate toposcopic delivery. As shown, filling catheter 400, such as a catheter described in the Dann '605 application, is placed in fluid communication with a device 416 that flushes filling catheter 400 with inflation media such as a fluid. Device 416 can comprise, for example, an electronic or hand-actuated piston or plunger, hand pump, impeller pump, or peristaltic pump. In some embodiments, an endoscope can flush filling catheter 400 with fluid. Device 416 can in turn be placed in fluid communication with a fluid source 420. For example, device 416 can be in fluid communication with a container 420 that holds fluid. Container 420 can hold volumes of fluid ranging from 0.25 liters to 15 liters. In preferred embodiments, container 420 holds between one and five liters. Device 420 can flush fluid through filling catheter 400 at a rate ranging from 5 cc to 100 cc per stroke or actuation of device 420. In preferred embodiments, device 420 flushes fluid through filling catheter 400 at a rate of 30 cc to 300 cc per stroke. Optionally, the filling catheter 400 or the device 416 can have a pressure or volume measurement device to measure the pressure or delivered volume of fluid that is used to evert the sleeve 100. This can be used as an alternative way to determine when the sleeve is fully deployed. The volume measurement can be used to determine when enough fluid has been delivered to fully deploy the sleeve 100. The pressure measurement can be used to detect the pressure drop once the sleeve is fully deployed and the distal end 112 of the sleeve opens up to allow the fluid to pass through with less back pressure.
[0083] In one embodiment, filling catheter 400 passes into the lumen of sleeve 100 and a fluid-tight seal 468 is created between the proximal end of sleeve 100 and filling catheter 400, as shown in FIG. 11. In an alternate embodiment, the distal end 112 of sleeve 100 passes proximally into the lumen of filling catheter 400, the proximal end of sleeve is concentrically positioned over the distal end of filling catheter 400, and a fluid-tight seal 468 is created between the proximal, inverted, outer surface of sleeve 100 and the distal end of filling catheter 400, as shown in Fig. 18. Tubing 470 can be utilized to provide a passageway between filling catheter 400 and device 416. In this embodiment, a temporary barrier 466 can be created at distal end 112 of sleeve 100. In preferred embodiments, temporary barrier 466 is created by collapse of distal end 112 caused by the influx of fluid through filling catheter 400. In other embodiments, distal end 112 can be blocked with an absorbable or degradable plug comprising cellulose, sugar-based substances, PLA, and any other materials as would be contemplated by those skilled in the art. Any of the techniques discussed above can also be used to create temporary barrier 466.
[0084] Many advantages are associated with toposcopic delivery of electrodes 12attached to a sleeve 100. Toposcopic delivery allows sleeve 100 to be delivered without moving electrodes 12 on sleeve 100 over and against the endothelium of the esophagus, stomach, and intestines. Sleeve 100 when delivered toposcopically can navigate tortuous anatomy. When sleeve 100 is delivered toposcopically, inverted portions of sleeve 100 deploy an axial elongation without axial sliding against the tissue such that there is no tissue abrasion and no kinks or twists are created in sleeve 100. Toposcopic delivery of electrodes 12 also requires minimal instrumentation development. The sleeve 100 delivered toposcopically is not limited to being attached to the cuff at the GEJ. The method of delivering an intestinal sleeve with a toposcopic delivery technique as described above can be used to attach a sleeve to the pylorus, the duodenal bulb, the lower portion of the stomach or anywhere else where it is deemed to be clinically beneficial.
[0085] Methods of insertion and retrieval of a gastrointestinal stimulation system including a sleeve are also described in, for example, the Dann '605 application and the Kagan '634 application. In addition to the methods described therein, a GI sleeve containing electrodes 12 can be inserted and/or retrieved using a flexible endoscope. A skilled GI endoscopist can "drive" a special endoscope (an enteroscope) through the duodenum and deep into the jejunum. Because of its small size, a pediatric colonoscope can be used to access an area further down the intestine. With proper interfacing structure on a GI sleeve, the sleeve can piggyback on the endoscope as it is driven into the jejunum and then released with its distal end left in the jejunum when the endoscope is retracted and removed from the body. This can be accomplished perorally either before or after attachment of the proximal end of the sleeve to tissue or to a cuff at the GEJ 106 or some other clinically desirable location. Toposcopic Delivery without Retaining a Bypass Sleeve
[0086] In some embodiments, as disclosed in the Dann '862 provisional application incorporated by reference in its entirety, all or part of the stimulation system may be delivered toposcopically without retaining a bypass sleeve within a body lumen after completion of the procedure. The delivered device may be an electrical stimulation component or any part thereof, such as one or more electrodes, or an alternative access system such as a guidewire or rail. The delivered device may be detached at the delivery site and left in place (an implant) or removed from the body following the diagnostic or therapeutic procedure.
[0087] Referring to FTG. 12A, there is illustrated a toposcopic delivery device in accordance with the present invention. The delivery device includes a filling catheter 400, illustrated as extending across the stomach such that a distal end 402 is in the vicinity of the pylorus 116. A toposcopic delivery sleeve 1000 (which can, in some embodiments, be essentially the same as a bypass sleeve 100 except removed after the procedure) may be is proximally retracted within the filling catheter 400. [0088] The distal end 112 of the toposcopic sleeve 1000 is closed, and provided with a connector 200. As illustrated in FlG. 12B and as will be apparent in view of the preceding discussion, the connector will advance distally in response to the introduction of inflation media through filling catheter 400.
[0089] The connector 200 may be removably or permanently connected to a device, such as, for example, a base stimulator, a biasing element, a conductive element, or an electrode, which maybe a wireless electrode. In FIG. 12A, the connector 200 is connected to a guidewire 152. As the sleeve 1000 is everted distally, the connector 200 advances distally, pulling guidewire 152 in a distal direction. In this manner, a guidewire 152 may be distally axially advanced through a tortuous pathway, within the sleeve 100.
[0090] Following complete evertion of the sleeve 1000, the connector 200 may be caused to release the guidewire 152. Release may be accomplished in any of a variety of ways, such as by introduction of a solvent through sleeve 1000, introduction of a solvent around the outside of the filling catheter 400, thermally releasing a polymeric link through the use of a monopolar or bipolar electrical circuit as is understood in the detachable intracranial aneurysm coil field, or the like. Alternatively, the guidewire 152 may comprise a hollow outer sleeve which axially slideably receives an inner core. Axial, proximal or distal displacement of the core with respect to the sleeve can be utilized to detach the connector 200. The guidewire may also be forceably detached, by a pushing, twisting or pulling motion.
[009X] Following detachment of connector 200 and opening of the distal end of the sleeve, the sleeve 1000 may be proximally retracted leaving the guidewire 152 in place. Alternatively, devices may be advanced along the guidewire 152 through the sleeve 1000, leaving the sleeve 1000 in position.
Additional Fastener Embodiments
[0092] A stimulation system as disclosed herein can be attached to the wall of the GI tract with any variety of fasteners known in the art. In some embodiments, a stimulation system is securing using fasteners disclosed in the Kagan '634 application, and discussed below. [0093] The present inventors believe that some areas of the esophageal or gastric wall exhibit physical properties more conducive to retaining attachment structures than other areas. For example, an attachment zone 1600, shown in FIG. 13 A, directly below the squamocolumnar junction (SCJ) 1620, also known as the Z-line, ora serrata, and mucosal gastroesophageal junction (GEJ) 106, may be such an area. The SCJ marks the junction of the squamous mucosa of the esophagus and the columnar or glandular mucosa of the stomach. The SCJ is typically located at or above the GEJ.
[0094] At least a portion of a gastrointestinal stimulation system may, in one preferred embodiment, be attached in an attachment zone 1600 no more than about 2 cm and preferably no more than about 1 cm below the SCJ 1620 and below the esophagus 1640 where the tissue wall thickness is thicker than the tissue wall thickness of the esophagus 1640 and where there exists a serosal outer surface not exhibited at the esophagus 1640. The device is also preferably attached at a location in the attachment zone 1600 so as to minimize the risk of reflux. The SCJ 1620 can be located relative to other anatomical regions. It normally may be found at the GEJ 106. The GEJ 106 is the region at which the tubular esophagus joins the saccular stomach. The GEJ 106 can be considered the first part of the stomach 1660 or the cardia and is located at the proximal margin of the longitudinal gastric mucosal folds or in the distal 2 cm of the esophagus 1640 and proximal stomach 1660. Endoscopically, the location of the GEJ 106 can be approximated by identifying the proximal margin of the gastric folds.
[0095] Due to patient to patient variability, as well as a variety of medical conditions, the anatomical relationships described above are not always found in all patients. For example, the location of the SCJ relative to the GEJ varies naturally patient to patient as well as due to certain medical conditions such as Barrett's esophagus.
[0096] Thus, a first aspect to the location of attachment of the devices disclosed herein relates to the position of the attachment structures along the axis of the hollow lumen or organ. As described above, the attachment location in the axial direction is preferably in the vicinity of the gastroesophageal junction, and particularly just below the SCJ. This attachment site can be located endoscopically by observing the color change which occurs at the SCJ, and advancing or positioning the attachment structures of the endoscope slightly below that line.
[0097] In some clinical situations the gastroesophageal junction, or GEJ 106, is a preferred attachment point for, for example a portion of a gastrointestinal stimulation system such as a gastroesophageal sleeve 100 or a stimulator base housing 6 as discussed above. Attachment at the GEJ 106 excludes all gastric secretions from the interior of the gastrointestinal sleeve device to separate ingested food and liquids in the sleeve device from all digestive secretions. The gastroesophageal junction is one of the preferred attachment sites because the tissue wall is relatively thick at this location and it is relatively easy to access via a peroral route. More specifically, the area directly below the squamo-columnar junction (a zone of tissue that is considered to be at or slightly above the beginning of the GEJ 106) is currently thought to be the best place to attach a device, for example using T- tags, sutures or other fasteners.
[0098] A second aspect to the location of the attachment structure relates to the depth within the adjacent tissue wall (i.e., in a transverse direction to the longitudinal axis of the esophagus described above) within which the various anchors or retention structures disclosed herein reside. Applicants believe that the location in the transverse direction is subject to migration or other change post-implantation, as described in connection with Figures 13B through 13D.
[0099] Referring to Figure 13B, there is disclosed a highly simplified schematic cross sectional view of a tissue wall such as the wall of a hollow organ or lumen in the body, including the wall at the vicinity of the gastroesophageal junction. The tissue wall comprises a serosa 170 and a muscularis 172. Additional tissue layers have been omitted for simplicity, hi general, as is appreciated by those of skill in the art, the serosa 170 is on the outside of or faces away from the stomach, and the muscularis is on the inside, or faces towards the interior of the stomach. The serosa 170 thus includes a serosal surface 174 which faces away from the interior of the stomach, and the muscularis 172 includes a muscularis surface 176 which faces towards the interior of the stomach.
[0100] An attachment device or anchor 178 is illustrated in part in Figures 13B through 13D. The attachment device 178 can take any of a variety of forms, described elsewhere herein. In general, the attachment device 178 includes a retention element 180 having at least one retention surface 182 thereon. The retention clement 180 may be integrally formed with or attached to a tension element 184, which extends through the tissue wall and is secured to the device implanted within the gastrointestinal tract. Although the attachment mechanisms disclosed herein will be defined primarily in the context of an obesity device, which is attached in the vicinity of the GEJ 106, those of skill in the art will appreciate that the attachment system disclosed herein may be utilized in any of a wide variety of other anatomical locations, such as in the bronchial tubes, urethra, ureters, fallopian tubes, throughout the GI tract, and others which share a serosa or serosa like layer, such as in the kidney, bladder, and other organs, as would be recognized by those skilled in the art.
[0101] Referring to Figure 13B, the retention element 180 is illustrated with the retention surface 182 residing against the serosal surface 174. Retention surface 182 may "comprise any of a variety of forms, such as a proximal surface on a T-tag, proximal surface on a washer or disc, or any other surface which extends in a generally lateral direction with respect to a longitudinal axis of the tension element 184. The transverse retention surface 182 may be radially enlargeable or expandable from a first;, reduced cross-sectional configuration to provide a low crossing profile such as for deployment through a deployment cannula, and a second, radially expanded or enlarged cross-sectional profile as illustrated in Figure 13B, to provide a retention surface 182 which will engage or interfere with tissue of the serosa 170 or muscularis 172 to resist proximal retraction of the attachment device 178 through the tissue. Transformation between the first configuration and second configuration can be accomplished in any of a variety of ways as is discussed further herein, such as by pivoting the retention element 180 about the attachment point to tension element 184, by radial expansion, by inflation, or other technique.
[0102] Tension element 184 may comprise any of a variety of connectors or elements adapted to extend through the tissue wall, such as a suture, or other single stand or multi-strand filament or material. In some embodiments the tension element 184 is formed of a polymer such as PEEK or silicone. The tension element 184 may also, in some embodiments, have elastic properties. In other embodiments the tension element 184 does not have elastic properties. By use of the term tension element, no specific mechanism is suggested, and the element is not required to be under mechanical tension.
[0103] The attachment device, otherwise sometimes referred to herein as a tissue anchor, T-tag or other label, it is illustrated in Figure 13B in a schematic fashion as it may appear at the time of implantation. Since in certain implementations of the invention the length of the tension element 184 will exceed the uncompressed thickness of the adjacent tissue wall, the retention surface 182 may even be spaced slightly apart from the serosal surface 174 depending upon the transient motion or configuration of the stomach at any given time.
[0104] Without being limited to any particular structure or mechanism, Applicants believe that the presence of the attachment device may cause or accelerate the formation of a layer 186 of serosal tissue having increased tissue density relative to unaffected or normal serosal tissue. The layer of increased density 186 may result from a process in which the transverse retention surface 182 places pressure against the serosa 170, causing a localized necrosis due to the restriction of capillary blood flow. The necrosed tissue thereafter fibroses, as a part of a normal healing response. The layer of increased density 186 or fibrosis may also result from a foreign body reaction triggered by the presence of the transverse retention surface 182. Applicants have observed a greater degree of fibrosis or denser tissue on the side of the T-tag facing the lumen of the stomach, for example on the retention surface 182.
[0105] In certain animal trials conducted by Applicants in which the animals were sacrificed five weeks following implantation of the attachment device 178, successful anchors appeared similar to the simplified schematic illustration of Figure 13C. In this illustration, the location of the retention element 180 has changed relative to the serosa 170 and muscularis 172, and the distal surface 188 of the retention element 180 has been covered with an overgrowth of serosal tissue 190. A fϊbrotic layer 186 is positioned in between the retention surface 182 and the muscularis 172. Although illustrated only on the proximal side of the retention element 180 where the greatest degree of fibrosis has been found to occur, the fϊbrotic response appears to some extent to surround and wall off the entire retention element 180. [0106] It appears to the present inventors that formation of a sufficient flbrotic response on the proximal side of the retention surface 182 decreases the likelihood that the attachment device 178 will relocate to the inside of the stomach under normal agitation of the stomach, changes in the thickness of the stomach wall, and other conditions normally occurring in the stomach. A similar response is schematically illustrated in Figure 13D, in which the layer 186 of high density serosal tissue remains on the proximal side of the retention element 180, however one or both of the layer 186 and retention element 180 have relocated to below the normal plane 192 separating the serosa 170 from the muscularis 172 and will remain there.
[0107] It appears to the present inventors that if the device design and/or retention element 180 design are such that in normal use the retention element 180 relocates to a position in the muscularis 172 and past the serosa 170 before a sufficient flbrotic response, the retention element 180 may relatively easily pass through the muscularis 172 and failure will result. Thus, it may be desirable in certain implementations of the invention to facilitate or accelerate the formation of the fϊbrotic layer 186. This may be accomplished in any of a variety of ways which will be appreciated by those of skill in the art in view of the present disclosure, such as by the introduction of an active agent which will trigger a fϊbrotic response. Suitable active agents may include any of a variety of growth factors, and/or chemical sclerosing agents which are well known for other medical applications. The surfaces of the retention element and tension element may also be provided with an antibacterial characteristic, such as by eluting an antibiotic agent, or having a bacteriostatic or bacteria inhibiting coating. Drug eluting coatings are well understood in the coronary stenting arts, and can be adapted for use in the present context by those of skill in the art.
[0108] Active agents may be applied as a coating to the retention surface 182 or retention element 180, or may be impregnated into the material of retention element 180 and/or tension element 184, such as to permit a timed release into adjacent tissue. Incorporation may be accomplished by loading the active agent into tortuous pathways or pores exposed to the surface of the retention element 180, or by inclusion in a bioabsorbable or bioerodable carrier attached to or positioned in the vicinity of the retention surface 182. Energy sources may also be utilized, such as to generate heat or otherwise stimulate formation of a fϊbrotic response, as is discussed further below. Formation of the fibrotic layer 186 may also be facilitated by mechanical means, for example, in one embodiment, by roughening the retention surface 182 with the addition of fibrotic layer enhancement structures such as a plurality of bumps or etched lines.
[0109] FIG. 13E shows an implanted gastrointestinal stimulation system 2001 including a sleeve 2000 attached by an attachment cuff 214 with the use of T-tags 207. Also shown schematically is stimulator base housing 6 operably attached to cuff 214, as well as conductive element 10 and electrodes 12 as previously described. FIG. 13F is an enlarged view of the attachment cuff 214 attached with T-tags 207 showing the transverse retention elements 209 of the T-tags 207 embedded in the stomach wall, as may be observed several weeks post implantation. Elements of the stimulator are not shown in FIG. 13F for clarity.
[0110] T-tag type fasteners can be used endoscopically to attach many of the structures described herein. A T-tag is basically a retention element 180 in the form of a cross member or "T" that is attached to a tension element 184 in the form of an elongated member or tail at or near the mid-point of the T. A "stem" may be a structure at the joining point of the T and tail. From the perspective of a peroral attachment technique, in which the attachment devices are preferably advanced through muscularis 172 in the direction of the serosa 170, the stem or tension element will be referred to herein as relatively proximal to the cross member on the T-tag. The T-tag is a member of a more general family of tissue anchors, in which a proximally facing surface 182 (such as the proximal surface of the cross member) is adapted to be bent, folded, or otherwise reduced in crossing profile to a first configuration in which it can be advanced distally through a relatively small tissue opening, to a second configuration in which it presents a proximal serosal surface contacting area for resisting proximal retraction through the access pathway. Thus, although described primarily in the context of a T-tag and variations thereof, the present invention relates more broadly to tissue anchors of the type for presenting a retention surface which may have any of a wide variety of configurations. Some are described in additional detail below. The stem may also be referred to herein as a tension member, and may comprise a suture, or other single strand or multi-strand element for drawing the tissue anchor against the serosal tissue and/or connecting the tissue anchor to the implantable cuff or other endolumenal implant. JOlIl] T-tag fasteners are generally configured to flex or pivot at the juncture of the T and tail to allow delivery along the axis of the T through a minimal puncture diameter. T-tag fasteners can be configured with an extended tail that may extend out the mouth and optionally be used to parachute devices for attachment into position in vivo. Other T-tag configurations can include, crimp, snap, screw or other means of securing the T-tag tail when appropriate. One embodiment of a T-tag fastener could include a dual tail. Such a dual tail could be combined with extended tails that could then be tied out side the body with the ensuing knots then tightened within the body. Such a dual tail could be constructed of one of a number of non-biodegradable suture materials known in the art including polypropylene, nylon, braided Dacron or silk. In some clinical situations biodegradable tails could be indicated and could be constructed using materials described herein. In a preferred embodiment the tails could be constructed of a monofilament material.
(0112] In certain implementations of the present invention, it may be desirable to increase the effective surface area of the retention surface 182. This may be accomplished using any of a variety of disc or button shaped attachment devices 178 disclosed herein, or by introducing a buttressing component or element in the nature of a washer or other structure for enlarging the effective surface area. This buttressing structure may sometimes be referred to herein as a pledget. The buttressing material is generally configured perpendicular to the axis of the tension element 184 (e.g. suture, rivet or staple) and therefore best distributes forces along the axis of the attachment means.
[0113] T-tags or other serosal anchors can be delivered through a hollow needle type delivery system (e.g. T-ANCHOR INTRODUCER GUN (Moss, Moss Tubes)) that has been redesigned/modified so it can be passed through the working channel of an endoscope. A T-tag can be provided with an elongated tail that can extent out through the mouth and be used to parachute structures into place in-vivo.
[0114] In one embodiment the T-tags are placed such that the sutures of the T- tags could be knotted outside of the body and the knots could be pushed down the working channel or outside of the working channel of the scope until positioned to retain the cuff. The suture tails could subsequently be removed. To facilitate management of all the suture tails, two T-tags could first be placed to secure the cuff followed by placement of the rest of the T-tags. In a preferred embodiment the T-tag tension elements, such as tails, sutures, or other structures as described herein, would terminate in the stomach, such as by tied knots, sliding buttons, or preexisting terminated ends, such that they would not need to be brought outside of the body.
[0115] As an alternative to tying sutures outside of the body, any of a variety of suture locks may be utilized to secure the suture with respect to the cuff. In general, a suture lock is provided with a central aperture for moveably receiving the suture therethrough. The lock may be configured for one way advance along the suture, having a spring biased engaging element for resisting movement of the lock in the opposite direction. Alternatively, a central plug may be advanced into the central lumen, to compress the suture within the suture lock and retain the suture lock at a selected position. Any of a variety of clips may also be axially or radially moved into position, to engage the lock with the suture. The suture lock may be advanced down the suture and positioned with the desired tension against the interior surface of the cuff, and activated as necessary to lock the suture lock in place. The remaining suture tail may be severed, using conventional endoscopic techniques.
[0116] Alternatively, the suture lock may be secured to the cuff 102 such as at an aperture of the cuff, prior to implantation of the cuff 102 in the patient.
[0117] Many of the serosal anchors described herein can be formed using a single piece of Polypropylene, Nylon, PEEK, silicone, or. other polymeric material well known in the art for use in construction sutures, which forms the "T" and tail as a single unit. Alternately two different materials can be combined, for example by insert molding, to achieve different properties of the "T" and tail. In another embodiment this could be combined with a "T" portion that is coated with a material selected for specific clinical properties such as encouraging or discouraging either in-growth or adhesion. The "T" portion may also be surrounded by another material such as ePTFE or Dacron graft material. "T" diameter or serosal surface contacting width can vary for example ranging from 0.5 mm to 3.0 mm in diameter for nylon or polypropylene with the typical "T" having a diameter of 1 -2 mm. A tail could be the dimension of a standard suture and could generally vary from 5- 0 to 0 (USP standard classification) though smaller or larger sizes may be appropriate in certain clinical situations. (0118] FIGS. 14A & 14B illustrate a curved T-member 300 for a T-tag fastener. The convex curved tissue-contacting surface 302 of the curved T-member 300 serves to distribute the attachment force for an implanted device smoothly across the tissue to minimize any stress concentrations or higher pressure spots that could cause tissue necrosis and/or erosion. The T member 300 has a double eyelet 304 for attachment of a suture or other filament. The T-member is preferably molded of a fairly rigid, high strength biocompatible polymer such as PEEK.
[0119] FIGS 15A-15B illustrate a T-tag fastener 2200 with a hydrogel disc 2204 that can be placed between the deployed T-member 2208 and the extragastric (serosal) surface. The disc 2204 could be delivered through the T-tag delivery needle, and unroll after passage through the needle. The hydrogel disc 2204 acts as a buttress or pledget to distribute the forces transmitted between the T-member 2208 and the extragastric surface and thereby it strengthens the attachment of the T-tag fastener 2200. The hydrogel used in FIGS. 15A-15B can optionally be replaced with alternate materials described herein for example silicone, NiTi and fluoropolymers. A Hydrogel or other buttress or Teflon pledget for a T-tag could also deploy in some other manner. The disc configuration shown can be replaced with for example, braided or woven wires or filaments that would expand/deploy after passage through the needle (FIGS. 16A-16B), a Malecot-style deployable tubular structure (FIGS. 17A-17B) or other expandable or deployable configuration (e.g. FIGS. 18A- 18B). Although FIGS 15A-15B, 16A-16B, 17A-17B, and 18A-18B illustrate T-tag fasteners, such as 2200 in FIGS 15A-15B used with T-members 2208, uses of the T-tag fasteners without T-members and just with the hydrogel disc 2204 of FIGS. 15A-15B or the woven filaments, Malecot- style tubular structure, or the expandable structure of FIGS 16A-16B, 17A-17B, and 18A- 18B, respectively, are also contemplated.
[0120] In the above examples where it has been suggested that a fixed distance between the T-member and the device it is being used to attach is desirable it has been suggested that in some cases a distance greater than the thickness of the captured gastric wall may be clinically indicated. This is due to the ability/tendency/possibility that the gastric wall could react to the presence of a foreign body (the attachment structures) by thickening. In this event, in some cases, it can be clinically preferable that the preset distance accommodate some or all of this increase in wall thickness.
[0121J In some embodiments, a T-tag or T-pledget could have a discrete layer of a fabric interspersed between the T-tag and the serosal surface. This can advantageously facilitate tissue ingrowth and/or enhance transmural fastening of the device. The fabric may be woven or non-woven. The fabric may be permeable or impermeable. Depending upon the desired performance, the fabric material may be one or more of: Dacron, Dulex Mesh (Bard), Dual Mesh (Gore), PTFE (Teflon), ePTFE, plastics such as polyvinyl chloride, polyurethanes, polypropylene, polyesters, silicons, fibrin glues, extracellular collagen matrix materials such as Veritas (from Synovis) or Durgen Plus (from Integra), Goretex (Gore), silver composites, silver alloys, or any other suitable material referenced in the present disclosure. Any of the above materials can be impregnated or coated with a silver compound such as silver nitrate or silver oxide depending on the desired clinical result.
[0122J Referring to FIGS. 19A-19D, retention elements 920 are designed for expandability. A T-tag or T-fastener can be used to provide knot free means to retain a suture against pull through of an associated anatomic structure. A further advantage of a T-tag is that the forces applied to the suture tail of the "T" are distributed over a larger area than a single stitch. This is accomplished by using a "T" dimensioned with a width wider than the diameter of the suture and a length longer than a typical bite or stitch. A disadvantage of a T- tag is that insertion of a T-tag through tissue potentially requires a hole many times, for example 5-15 times, the diameter of the suture tail.
[0123J To deliver an improved buttressing capability in a T-tag fastener or T- pledget with a minimum delivery hole it is beneficial to use a "T" or pledget designed to expand after delivery. This can be beneficial in many clinical situations. In addition to rolling or compressing, alternate structures can include materials that expand when exposed to water such as hydrogels. FIGS. 19C and 19D show how a T-pledget 920 or T-tag of woven cylindrical meshes that may be compressed or elongated to achieve a reduced diameter and expanded or shortened to become wider. Compared to a rectangular sheet, alternate configurations of a rolled and unrolled sheet can achieve a T-pledget 920 or T-tag with increased projected width relative to its rolled diameter through the use of matching cutouts, as shown in FIGS. 19A and 19B. Though not as efficient in diameter-to-projected width ratio, is some cases it may be clinically desirable to have a "T" that is in a circular shape.
[0124] To resist bending perpendicular to the axis of the suture, it may be beneficial to use metals, for example Ti, SS or NiTi. In some clinical situations, encapsulating or coating the metal with a fluoropolymer or other coatings as described herein may also be beneficial.
[0125] T-tag with inflammatory reaction or other additives— The pledget material could be optionally coated or impregnated with materials and/or medicaments as described herein. For example the pledget can be coated with a material that would enhance inflammation and scar formation. Alternatively, a coating or medicament that would either encourage or discourage in-growth can be applied.
[0126] In some clinical situations it may be beneficial to use both these types of coatings. For example, though inflammation can lead to scarring fibrosis and ultimately strengthen tissue, the inflammatory process initially results in tissue weakening that can include tissue liquefaction. Therefore, it can be desirable that a fastener that induces an inflammatory response for long term strength also include means to support the tissue during the weakened stage.
[0127] Inflammatory reaction materials would be limited to a portion of the T-tag or T-pledget as the inflammatory response weakens tissue before the scarring fibrosis occurs. Therefore, for example, having the area at the center of the T or pledget with this inflammatory material and the ends of the "T" without this material could have an optimized balance of short term and long term strength.
[0128] Drug-eluting coatings may be used to encourage or discourage tissue ingrowth into the fasteners or other device attachment mechanisms described herein. A low inflammatory response is generally desirable for encouraging tissue ingrowth. Antiinflammatory drugs that may be used include steroidal anti-inflammatory drugs, e.g. prednisone, and nonsteroidal anti-inflammatory drugs (NSAID), e.g. chromalin. Conversely, drugs that may be used to control or reduce tissue ingrowth include Taxol (paclitaxel) (Bristol-Myers Squibb) and Sirolimus (rapamycin) (Wyeth-Ayerst Laboratories). [0129] Embodiments designed for improved erosion resistance—The purpose of the "T" or other retention element is to distribute and resist the forces that could act to pull it through tissue, in this case the gastric wall. To better achieve this result the "T" should resist excessive bending. Though a T-fastener is generally held parallel to the surface of the extragastric wall, at the ends of the "T" the gastric wall extends outward from the plane of the surface and the axis of the "T". In this case, the gastric wall could be at a 90-degree angle, or greater, to the ends of the "T". To reduce the potential for erosion at the end of the "T" in some clinical situations it could be beneficial for the ends of the "T" to have increased flexibility which will result in a reduction of the angle between the gastric wall and the ends of the "T". This would reduce the forces between the "T" and the gastric wall and therefore reduce the potential for erosion at the ends. Structures that could accomplish this could include tapered thickness or cross section to reduce the bending moment. Alternatively or in addition, changes in material properties such as hardness, bending modulus and/or elongation can accomplish the same result. For example the "T" near the stem could be of a material of a durometer such as Shore 65D or higher and the material may change as one moves out along the arms of the "T" transitioning through 55D/100A to 9OA durometer or lower. Rounding, smoothing and structures that otherwise distribute forces over a larger area will also serve to reduce erosion at the ends of the "T". A circular shaped "T" may be particularly desirable to reduce erosion.
(0130] In some embodiments, the base stimulator housing 6 could be positioned on the serosal surface of the esophagus, GEJ, stomach, or intestine while the conductive element is wired through to the mucosal luminal side of the wall.
Dual-Therapy Systems for Gastric and/or Intestinal Bypass + Electrical Stimulation
[0131] In some embodiments, a system includes an endolumenal bypass sleeve as described herein in combination with any of the stand-alone electrical stimulation (pacing) devices known in the art. Conventional electrostimulation devices may be used in the practice of this invention. Such devices include, for example, those described in U.S. Pat. No. 5,423,872 (Jun. 3, 1995) (an implantable gastric electrical stimulator at the antrum area of the stomach which generates sequential electrical pulses to stimulate the entire stomach, thereby artificially altering the natural gastric motility to prevent emptying or to slow down food transit through the stomach); U.S. Pat. No. 5,690,691 (Nov. 25, 1997) (a portable or implantable gastric pacemaker employing a number of electrodes along the greater curvature of the stomach for delivering phased electrical stimulation at different locations to accelerate or attenuate peristaltic movement in the GI tract); U.S. Pat. No. 5,836,994 (Nov. 17, 1998) (an implantable gastric stimulator which incorporates direct sensing of the intrinsic gastric electrical activity by one or more sensors of predetermined frequency bandwidth for application or cessation of stimulation based on the amount of sensed activity); U.S. Pat. No. 5,861,014 (Jan. 19, 1999) (an implantable gastric stimulator for sensing abnormal electrical activity of the gastrointestinal tract so as to provide electrical stimulation for a preset time period or for the duration of the abnormal electrical activity to treat gastric rhythm abnormalities); PCT Publication WO 1998/053878 and U.S. Patent No. 6,321,124 (Nov. 20, 2001)(implant device equipped with tines to help secure it in the appropriate location); U.S. Pat. No. 6,041,258 (Mar. 21, 2000) (electrostimulation device with improved handle for laparoscopic surgery); U.S. Pat. No. 6,510,332 (Jan. 21, 2003); PCT Publication WO 2000/061224 entitled "Gastric Stimulator Apparatus and Method for Installing"; PCT Publication WO 2000/061223 entitled "Gastric Stimulator Apparatus and Method for Use"; and U.S. Patent Publication No. 2004-0162595 Al entitled "Method and Apparatus for Intentional Impairment of Gastric Motility and/or Efficiency by Triggered Electrical Stimulation of the Gastric Tract with Respect to the Intrinsic Gastric Electrical Activity." All of these patents, patent applications, and/or publications are hereby incorporated by reference in their entirety.
[0132] Such a dual-therapy system could be advantageous as a sleeve could be initially implanted to accelerate weight loss, while the pacer/stimulator could be retained for maintenance. The sleeve and stimulator could be both implanted in a first procedure. Once a desired clinical endpoint is reached, one of the sleeve or stimulator can be removed in a second procedure, while the other of the sleeve or stimulator retained within the body. In another embodiment, the sleeve and stimulator are implanted in separate procedures.
[0133] While this invention has been particularly shown and described with references to embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention. For all of the embodiments described above, the steps of the methods need not be performed sequentially.

Claims

WHAT IS CLAIMED IS:
1. A gastrointestinal stimulation system, comprising: a gastrointestinal bypass sleeve; and an electrical stimulator component.
2. The gastrointestinal stimulation system of Claim 1, wherein the electrical stimulator component is attached to the sleeve.
3. The gastrointestinal stimulation system of Claim I5 further comprising a gastrointestinal attachment cuff having a tubular body, a proximal end and a distal end.
4. The gastrointestinal stimulation system of Claim 1, wherein the electrical stimulator component comprises a circuit board and a battery; a conductive element; and at least one electrode.
5. The gastrointestinal stimulation system of Claim 4, wherein the battery is configured to be recharged using RF energy.
6. The gastrointestinal stimulation system of Claim 4, wherein the conductive element is a ribbon.
7. The gastrointestinal stimulation system of Claim 6, wherein the ribbon has one of a U-shaped or S-shaped cross-section.
8. The gastrointestinal stimulation system of Claim 4, wherein the circuit board and battery are hermetically sealed in a base housing.
9. The gastrointestinal stimulation system of Claim 8, wherein the base housing is attached to the outer diameter of the sleeve.
10. The gastrointestinal stimulation system of Claim I3 wherein the electrical stimulator is triggered by a sensor configured to detect one of the group selected from: pressure, temperature, pH, motion, and strain.
11. The gastrointestinal stimulation system of Claim 4, wherein the electrode is annular band-shaped.
12. The gastrointestinal stimulation system of Claim 4, wherein the conductive element is a lead wire.
13. The gastrointestinal stimulation system of Claim 4, further comprising at least one biasing element operably connected to an electrode.
14. The gastrointestinal stimulation system of Claim 13, wherein the biasing element is configured to increase one of the contact surface area or the contact surface time between the electrode and a lumen of the gastrointestinal tract.
15. The gastrointestinal stimulation system of Claim 13, wherein the biasing element is a continuous helical band.
16. The gastrointestinal stimulation system of Claim 13, wherein the biasing element is a ring.
17. The gastrointestinal stimulation system of Claim 13, wherein the biasing element is a flexible tube, and the electrode is positioned on an outer surface of the tube.
18. The gastrointestinal stimulation system of Claim 1, wherein the gastrointestinal bypass sleeve is at least partially inverted within itself, and adapted for eversion within the gastrointestinal tract.
19. The gastrointestinal stimulation system of Claim 1, wherein at least part of the electrical stimulation component is attached to a serosal surface of a wall of the gastrointestinal tract.
20. A gastrointestinal stimulation system, comprising: a electrical stimulator component, the stimulator component comprising a circuit board and a power source contained within a base housing; a conductive element; and at least one electrode; wherein the stimulator component is configured to be transmurally attached with at least one tissue anchor to a wall of the gastrointestinal tract.
PCT/US2007/009956 2006-04-25 2007-04-25 Methods and devices for gastrointestinal stimulation WO2007127209A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79477206P 2006-04-25 2006-04-25
US60/794,772 2006-04-25

Publications (2)

Publication Number Publication Date
WO2007127209A2 true WO2007127209A2 (en) 2007-11-08
WO2007127209A3 WO2007127209A3 (en) 2008-03-27

Family

ID=38656142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/009956 WO2007127209A2 (en) 2006-04-25 2007-04-25 Methods and devices for gastrointestinal stimulation

Country Status (2)

Country Link
US (2) US7881797B2 (en)
WO (1) WO2007127209A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8702642B2 (en) 2009-07-10 2014-04-22 Metamodix, Inc. External anchoring configurations for modular gastrointestinal prostheses
US9044300B2 (en) 2009-04-03 2015-06-02 Metamodix, Inc. Gastrointestinal prostheses
US9173760B2 (en) 2009-04-03 2015-11-03 Metamodix, Inc. Delivery devices and methods for gastrointestinal implants
US9278019B2 (en) 2009-04-03 2016-03-08 Metamodix, Inc Anchors and methods for intestinal bypass sleeves
US9622897B1 (en) 2016-03-03 2017-04-18 Metamodix, Inc. Pyloric anchors and methods for intestinal bypass sleeves
US10159699B2 (en) 2013-01-15 2018-12-25 Metamodix, Inc. System and method for affecting intestinal microbial flora
US10413209B2 (en) 2014-02-12 2019-09-17 The Methodist Hospital Method and apparatus for identifying the ureter during a minimally-invasive procedure
US10751209B2 (en) 2016-05-19 2020-08-25 Metamodix, Inc. Pyloric anchor retrieval tools and methods

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6675809B2 (en) * 2001-08-27 2004-01-13 Richard S. Stack Satiation devices and methods
US7097665B2 (en) 2003-01-16 2006-08-29 Synecor, Llc Positioning tools and methods for implanting medical devices
US6845776B2 (en) * 2001-08-27 2005-01-25 Richard S. Stack Satiation devices and methods
CN101810521B (en) 2001-08-27 2015-05-13 辛尼科有限责任公司 Satiation devices and methods
US7146984B2 (en) * 2002-04-08 2006-12-12 Synecor, Llc Method and apparatus for modifying the exit orifice of a satiation pouch
US8845672B2 (en) * 2002-05-09 2014-09-30 Reshape Medical, Inc. Balloon system and methods for treating obesity
US9060844B2 (en) * 2002-11-01 2015-06-23 Valentx, Inc. Apparatus and methods for treatment of morbid obesity
US7837669B2 (en) * 2002-11-01 2010-11-23 Valentx, Inc. Devices and methods for endolumenal gastrointestinal bypass
US7794447B2 (en) * 2002-11-01 2010-09-14 Valentx, Inc. Gastrointestinal sleeve device and methods for treatment of morbid obesity
WO2004049982A2 (en) 2002-12-02 2004-06-17 Gi Dynamics, Inc. Bariatric sleeve
US7608114B2 (en) 2002-12-02 2009-10-27 Gi Dynamics, Inc. Bariatric sleeve
US7025791B2 (en) * 2002-12-02 2006-04-11 Gi Dynamics, Inc. Bariatric sleeve
US8206456B2 (en) 2003-10-10 2012-06-26 Barosense, Inc. Restrictive and/or obstructive implant system for inducing weight loss
US20050247320A1 (en) 2003-10-10 2005-11-10 Stack Richard S Devices and methods for retaining a gastro-esophageal implant
JP4669480B2 (en) 2003-12-09 2011-04-13 ジーアイ・ダイナミックス・インコーポレーテッド Intestinal sleeve
EP1750595A4 (en) * 2004-05-07 2008-10-22 Valentx Inc Devices and methods for attaching an endolumenal gastrointestinal implant
US20060155375A1 (en) * 2004-09-27 2006-07-13 Jonathan Kagan Devices and methods for attachment of a gastrointestinal sleeve
US20080190989A1 (en) * 2005-10-03 2008-08-14 Crews Samuel T Endoscopic plication device and method
US20070100368A1 (en) * 2005-10-31 2007-05-03 Quijano Rodolfo C Intragastric space filler
US7881797B2 (en) * 2006-04-25 2011-02-01 Valentx, Inc. Methods and devices for gastrointestinal stimulation
US7894906B2 (en) 2006-06-06 2011-02-22 Cardiac Pacemakers, Inc. Amelioration of chronic pain by endolymphatic stimulation
US20070282376A1 (en) * 2006-06-06 2007-12-06 Shuros Allan C Method and apparatus for neural stimulation via the lymphatic system
US7734341B2 (en) * 2006-06-06 2010-06-08 Cardiac Pacemakers, Inc. Method and apparatus for gastrointestinal stimulation via the lymphatic system
US8905999B2 (en) * 2006-09-01 2014-12-09 Cardiac Pacemakers, Inc. Method and apparatus for endolymphatic drug delivery
US8109895B2 (en) * 2006-09-02 2012-02-07 Barosense, Inc. Intestinal sleeves and associated deployment systems and methods
EP2068719B1 (en) * 2006-09-15 2017-10-25 Boston Scientific Scimed, Inc. System for anchoring stomach implant
US8118774B2 (en) * 2006-09-25 2012-02-21 Valentx, Inc. Toposcopic access and delivery devices
US9037244B2 (en) 2007-02-13 2015-05-19 Virender K. Sharma Method and apparatus for electrical stimulation of the pancreatico-biliary system
US8226602B2 (en) 2007-03-30 2012-07-24 Reshape Medical, Inc. Intragastric balloon system and therapeutic processes and products
US20080294228A1 (en) * 2007-05-23 2008-11-27 Cardiac Pacemakers Method and device for controlled stimulation of lymphatic flow
WO2008154450A1 (en) * 2007-06-08 2008-12-18 Valentx, Inc. Methods and devices for intragastric support of functional or prosthetic gastrointestinal devices
US20090012544A1 (en) * 2007-06-08 2009-01-08 Valen Tx, Inc. Gastrointestinal bypass sleeve as an adjunct to bariatric surgery
EP2157919A4 (en) * 2007-06-11 2011-06-22 Valentx Inc Endoscopic delivery devices and methods
US8142469B2 (en) * 2007-06-25 2012-03-27 Reshape Medical, Inc. Gastric space filler device, delivery system, and related methods
WO2009013749A2 (en) * 2007-07-24 2009-01-29 Betastim, Ltd. Duodenal eating sensor
US8020741B2 (en) 2008-03-18 2011-09-20 Barosense, Inc. Endoscopic stapling devices and methods
US20110040232A1 (en) * 2008-04-23 2011-02-17 Duo-Cure, Inc. Duodenal liner device
US8828090B2 (en) * 2008-08-13 2014-09-09 Binerix Medical Ltd. Liner for tubular body portion and apparatus and methods for application thereof
US10603489B2 (en) 2008-10-09 2020-03-31 Virender K. Sharma Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage
WO2010042686A1 (en) 2008-10-09 2010-04-15 Sharma Virender K Method and apparatus for stimulating the vascular system
CN102281834B (en) * 2008-10-10 2017-08-22 卡斯滕·尼尔斯·古特 Device for implantation and the method for implantation
US7934631B2 (en) 2008-11-10 2011-05-03 Barosense, Inc. Multi-fire stapling systems and methods for delivering arrays of staples
JP5670424B2 (en) 2009-04-03 2015-02-18 リシェイプ メディカル, インコーポレイテッド Improved gastric space filling and manufacturing method including in vitro testing
US8224449B2 (en) * 2009-06-29 2012-07-17 Boston Scientific Neuromodulation Corporation Microstimulator with flap electrodes
US20100331621A1 (en) * 2009-06-30 2010-12-30 Gyrus Acmi, Inc. Bipolar resection device having simplified rotational control and better visualization
EP2456507A4 (en) 2009-07-22 2013-07-03 Reshape Medical Inc Retrieval mechanisms for implantable medical devices
EP2456505B1 (en) 2009-07-23 2017-05-24 ReShape Medical, Inc. Deflation and removal of implantable medical devices
US9604038B2 (en) 2009-07-23 2017-03-28 Reshape Medical, Inc. Inflation and deflation mechanisms for inflatable medical devices
WO2011038270A2 (en) 2009-09-24 2011-03-31 Reshape Medical, Inc. Normalization and stabilization of balloon surfaces for deflation
AU2010308498B2 (en) 2009-10-21 2016-02-11 Apollo Endosurgery, Inc. Bariatric device and method for weight loss
WO2011097636A1 (en) 2010-02-08 2011-08-11 Reshape Medical, Inc. Improved and enhanced aspiration processes and mechanisms for intragastric devices
WO2011097637A1 (en) 2010-02-08 2011-08-11 Reshape Medical, Inc. Materials and methods for improved intragastric balloon devices
EP2539011A4 (en) 2010-02-25 2014-03-26 Reshape Medical Inc Improved and enhanced explant processes and mechanisms for intragastric devices
ES2536055T3 (en) 2010-03-15 2015-05-20 Apollo Endosurgery, Inc. Bariatric device and weight loss method
EP2555705A4 (en) * 2010-04-06 2014-01-15 Reshape Medical Inc Inflation devices for intragastric devices with improved attachment and detachment and associated systems and methods
EP3949901A1 (en) * 2010-04-12 2022-02-09 Implantica Patent Ltd System for treating a patient having an intestinal disorder
WO2011139873A2 (en) * 2010-04-29 2011-11-10 Tufts University Sleeve for stimulation of tissue regeneration
KR101160646B1 (en) * 2010-05-14 2012-06-29 신경민 Abstinence-only stent on the prevention of food emissions
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
EP2595693B1 (en) 2010-07-22 2015-03-04 Endobetix Ltd Pancreatiobiliary diversion device
ES2565348T3 (en) 2010-10-18 2016-04-04 Apollo Endosurgery, Inc. Intragastric implant reagent devices
US8870966B2 (en) 2010-10-18 2014-10-28 Apollo Endosurgery, Inc. Intragastric balloon for treating obesity
US9463107B2 (en) 2010-10-18 2016-10-11 Apollo Endosurgery, Inc. Variable size intragastric implant devices
US9233016B2 (en) 2010-10-18 2016-01-12 Apollo Endosurgery, Inc. Elevating stomach stimulation device
WO2012054514A2 (en) 2010-10-18 2012-04-26 Allergan, Inc. Intragastric implants with duodenal anchors
US8920447B2 (en) 2010-10-19 2014-12-30 Apollo Endosurgery, Inc. Articulated gastric implant clip
US8864840B2 (en) 2010-10-19 2014-10-21 Apollo Endosurgery, Inc. Intragastric implants with collapsible frames
US9398969B2 (en) 2010-10-19 2016-07-26 Apollo Endosurgery, Inc. Upper stomach gastric implants
US9198790B2 (en) 2010-10-19 2015-12-01 Apollo Endosurgery, Inc. Upper stomach gastric implants
ES2593753T3 (en) 2010-10-19 2016-12-13 Apollo Endosurgery, Inc. Duodenal sleeve with anchor without perforation
US9095405B2 (en) 2010-10-19 2015-08-04 Apollo Endosurgery, Inc. Space-filling intragastric implants with fluid flow
US9498365B2 (en) 2010-10-19 2016-11-22 Apollo Endosurgery, Inc. Intragastric implants with multiple fluid chambers
US9017323B2 (en) 2010-11-16 2015-04-28 Tva Medical, Inc. Devices and methods for forming a fistula
JP2014512867A (en) 2011-02-09 2014-05-29 シー・アール・バード・インコーポレーテッド T-fastener suture feed system
US8888732B2 (en) * 2011-03-11 2014-11-18 Apollo Endosurgery, Inc. Intraluminal sleeve with active agents
US8599009B2 (en) 2011-08-16 2013-12-03 Elwha Llc Systematic distillation of status data relating to regimen compliance
US9010609B2 (en) * 2012-01-26 2015-04-21 Covidien Lp Circular stapler including buttress
US10576278B2 (en) 2012-02-21 2020-03-03 Virender K. Sharma System and method for electrical stimulation of anorectal structures to treat urinary dysfunction
US8706234B2 (en) 2012-02-21 2014-04-22 Virender K. Sharma System and method for electrical stimulation of anorectal structures to treat anal dysfunction
US9782583B2 (en) 2012-02-21 2017-10-10 Virender K. Sharma System and method for electrical stimulation of anorectal structures to treat urinary dysfunction
US8986337B2 (en) 2012-02-24 2015-03-24 Elwha Llc Devices, systems, and methods to control stomach volume
US20130324906A1 (en) 2012-05-31 2013-12-05 Valen Tx, Inc. Devices and methods for gastrointestinal bypass
US9681975B2 (en) 2012-05-31 2017-06-20 Valentx, Inc. Devices and methods for gastrointestinal bypass
US8956318B2 (en) 2012-05-31 2015-02-17 Valentx, Inc. Devices and methods for gastrointestinal bypass
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
US9486276B2 (en) 2012-10-11 2016-11-08 Tva Medical, Inc. Devices and methods for fistula formation
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US9757264B2 (en) 2013-03-13 2017-09-12 Valentx, Inc. Devices and methods for gastrointestinal bypass
US10821217B2 (en) 2013-03-14 2020-11-03 Tva Medical, Inc. Fistula formation devices and methods therefor
ES2880834T3 (en) * 2013-03-14 2021-11-25 Synerz Medical Inc Intragastric device to treat obesity
WO2015138998A1 (en) 2014-03-14 2015-09-17 Tva Medical, Inc. Fistula formation devices and methods therefor
WO2015153427A1 (en) * 2014-03-31 2015-10-08 Regents Of The University Of Minnesota Systems and methods for electrical stimulation of the gastrointestinal tract for treatment of post-operative ileus
EP3160388B1 (en) 2014-06-26 2021-08-11 Boston Scientific Scimed Inc. Medical devices to prevent bile reflux after bariatric procedures
WO2016033374A1 (en) 2014-08-27 2016-03-03 Tva Medical, Inc. Cryolipopysis devices and methods therefor
CN106999272B (en) 2014-09-18 2018-12-11 波士顿科学国际有限公司 The device for Weight reduction bracket for allowing pyloric sphincter normally to play a role
EP3200724A4 (en) * 2014-09-29 2018-03-28 The Regents of The University of California Flexible and stretchable electrodes for gastrointestinal implants
US10603490B2 (en) 2014-10-23 2020-03-31 The Foundry Llc Temporarily implantable GI sensor and stimulator and related methods
GB2532044A (en) * 2014-11-06 2016-05-11 Phagenesis Ltd Catheter for recovery of dysphagia
US10603040B1 (en) 2015-02-09 2020-03-31 Tva Medical, Inc. Methods for treating hypertension and reducing blood pressure with formation of fistula
AU2016335755B2 (en) * 2015-10-07 2021-07-01 Mayo Foundation For Medical Education And Research Electroporation for obesity or diabetes treatment
JP6894440B2 (en) 2016-01-15 2021-06-30 ティーブイエー メディカル, インコーポレイテッド Devices and methods for forming fistulas
US10874422B2 (en) 2016-01-15 2020-12-29 Tva Medical, Inc. Systems and methods for increasing blood flow
JP6979021B2 (en) 2016-01-15 2021-12-08 ティーブイエー メディカル, インコーポレイテッド Devices and methods for advancing wires
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US11285028B2 (en) 2016-09-25 2022-03-29 Tva Medical, Inc. Vascular stent devices and methods
EP3723875A4 (en) * 2017-12-13 2021-09-08 Pelvital USA, Inc. Apparatus, system, and method for tissue regeneration
CN112138280B (en) * 2020-09-19 2023-06-02 西安交通大学医学院第一附属医院 Therapeutic apparatus with infinite electric stimulation function for resisting gastroesophageal reflux disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092892A1 (en) * 2002-11-01 2004-05-13 Jonathan Kagan Apparatus and methods for treatment of morbid obesity
US20060247718A1 (en) * 2005-04-28 2006-11-02 Medtronic, Inc. Dual mode electrical stimulation to treat obesity
US20060265021A1 (en) * 2004-03-16 2006-11-23 Medtronic, Inc. Intra-Luminal Device for Gastrointestinal Electrical Stimulation

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3589356A (en) 1969-09-04 1971-06-29 Daniel Silverman Method for everting and extraverting flexible tubing into a body cavity
DE2462537C3 (en) 1974-05-02 1979-05-03 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Catheter device
US3982544A (en) 1974-11-18 1976-09-28 Johnson & Johnson Device for everting a probe into a body cavity
US4006747A (en) 1975-04-23 1977-02-08 Ethicon, Inc. Surgical method
US4109659A (en) 1976-07-19 1978-08-29 Mallinckrodt, Inc. Evagination catheters
US4315509A (en) 1977-01-10 1982-02-16 Smit Julie A Insertion and removal catheters and intestinal tubes for restricting absorption
US4134405A (en) 1977-01-10 1979-01-16 Smit Julie A Catheter and intestine tube and method of using the same
US4252131A (en) 1978-04-17 1981-02-24 American Home Products Corporation Catheter for measuring intrauterine pressure
US4235238A (en) 1978-05-11 1980-11-25 Olympus Optical Co., Ltd. Apparatus for suturing coeliac tissues
WO1980000007A1 (en) 1978-06-02 1980-01-10 A Rockey Medical sleeve
US4217664A (en) 1979-02-02 1980-08-19 Faso Joseph M Prosthesis and method for creating a stoma
US4271839A (en) 1979-07-25 1981-06-09 Thomas J. Fogarty Dilation catheter method and apparatus
US4329995A (en) 1980-08-29 1982-05-18 Board Of Regents, The University Of Texas System Catheter for nasotracheal aspiration of uncontaminated sputum specimens
US4630609A (en) 1981-05-14 1986-12-23 Thomas J. Fogarty Dilatation catheter method and apparatus
US4606347A (en) 1983-03-25 1986-08-19 Thomas J. Fogarty Inverted balloon catheter having sealed through lumen
US4532926A (en) 1983-06-20 1985-08-06 Ethicon, Inc. Two-piece tissue fastener with ratchet leg staple and sealable latching receiver
US4719916A (en) 1983-10-03 1988-01-19 Biagio Ravo Intraintestinal bypass tube
US4905693A (en) 1983-10-03 1990-03-06 Biagio Ravo Surgical method for using an intraintestinal bypass graft
US4763653A (en) 1985-02-19 1988-08-16 Rockey Arthur G Medical sleeve
USRE34021E (en) 1985-11-18 1992-08-04 Abbott Laboratories Percutaneous fixation of hollow organs
US4863440A (en) 1985-12-23 1989-09-05 Thomas J. Fogarty Pressurized manual advancement dilatation catheter
FR2614626B1 (en) 1987-04-30 1989-07-21 Ranoux Claude CONTAINER FOR FERTILIZATION OF OVOCYTES AND REPLACEMENT OF EMBRYOS IN HUMANS AND ANIMALS
US4846836A (en) 1988-10-03 1989-07-11 Reich Jonathan D Artificial lower gastrointestinal valve
US4946440A (en) 1988-10-05 1990-08-07 Hall John E Evertible membrane catheter and method of use
US5236423A (en) 1988-12-13 1993-08-17 Endomed Corporation Facilitating endoscopy
US5314473A (en) 1989-07-20 1994-05-24 Godin Norman J Prosthesis for preventing gastric reflux into the esophagus
US5085661A (en) 1990-10-29 1992-02-04 Gerald Moss Surgical fastener implantation device
US5171305A (en) 1991-10-17 1992-12-15 Imagyn Medical, Inc. Linear eversion catheter with reinforced inner body extension
US5197649A (en) 1991-10-29 1993-03-30 The Trustees Of Columbia University In The City Of New York Gastrointestinal endoscoptic stapler
US5458573A (en) 1992-05-01 1995-10-17 American Biomed, Inc. Everting toposcopic dilation catheter
US5306300A (en) 1992-09-22 1994-04-26 Berry H Lee Tubular digestive screen
US5431666A (en) 1994-02-24 1995-07-11 Lasersurge, Inc. Surgical suture instrument
US5470337A (en) 1994-05-17 1995-11-28 Moss; Gerald Surgical fastener
US5582616A (en) 1994-08-05 1996-12-10 Origin Medsystems, Inc. Surgical helical fastener with applicator
US5972023A (en) 1994-08-15 1999-10-26 Eva Corporation Implantation device for an aortic graft method of treating aortic aneurysm
AU3783195A (en) 1994-11-15 1996-05-23 Advanced Cardiovascular Systems Inc. Intraluminal stent for attaching a graft
US5676688A (en) 1995-02-06 1997-10-14 Rtc, Inc. Variably inflatable medical device
US5904697A (en) 1995-02-24 1999-05-18 Heartport, Inc. Devices and methods for performing a vascular anastomosis
CH688174A5 (en) 1995-03-28 1997-06-13 Norman Godin Prosthesis to oppose the gastric reflux into the esophagus.
US5785684A (en) 1996-02-06 1998-07-28 Zimmon Science Corporation Apparatus and method for the deployment of an esophagastric balloon tamponade device
US5645568A (en) 1995-11-20 1997-07-08 Medicinelodge, Inc. Expandable body suture
US6001110A (en) 1997-06-20 1999-12-14 Boston Scientific Corporation Hemostatic clips
US5944750A (en) 1997-06-30 1999-08-31 Eva Corporation Method and apparatus for the surgical repair of aneurysms
US5957940A (en) 1997-06-30 1999-09-28 Eva Corporation Fasteners for use in the surgical repair of aneurysms
US5997556A (en) 1997-06-30 1999-12-07 Eva Corporation Surgical fastener
US5820584A (en) 1997-08-28 1998-10-13 Crabb; Jerry A. Duodenal insert and method of use
US5887594A (en) 1997-09-22 1999-03-30 Beth Israel Deaconess Medical Center Inc. Methods and devices for gastroesophageal reflux reduction
FR2769491B1 (en) 1997-10-15 2000-01-07 Patrick Sangouard ADJUSTABLE ARTIFICIAL SPHINCTER WITH MAGNETIC CONTROL
US6551328B2 (en) 1997-11-03 2003-04-22 Symbiosis Corporation Surgical instrument for invagination and fundoplication
US6086600A (en) 1997-11-03 2000-07-11 Symbiosis Corporation Flexible endoscopic surgical instrument for invagination and fundoplication
US6254642B1 (en) 1997-12-09 2001-07-03 Thomas V. Taylor Perorally insertable gastroesophageal anti-reflux valve prosthesis and tool for implantation thereof
US6626919B1 (en) 1997-12-29 2003-09-30 Lee L. Swanstrom Method and apparatus for attaching or locking an implant to an anatomic vessel or hollow organ wall
US7468060B2 (en) 1998-02-19 2008-12-23 Respiratory Diagnostic, Inc. Systems and methods for treating obesity and other gastrointestinal conditions
US6706051B2 (en) 1998-04-08 2004-03-16 Bhk Holding, Ltd. Hemostatic system for body cavities
US6113609A (en) 1998-05-26 2000-09-05 Scimed Life Systems, Inc. Implantable tissue fastener and system for treating gastroesophageal reflux disease
US6264700B1 (en) 1998-08-27 2001-07-24 Endonetics, Inc. Prosthetic gastroesophageal valve
US6746489B2 (en) 1998-08-31 2004-06-08 Wilson-Cook Medical Incorporated Prosthesis having a sleeve valve
AU1405600A (en) 1998-12-01 2000-06-19 Atropos Limited A medical device comprising an evertable sleeve
ATE543442T1 (en) 1998-12-31 2012-02-15 Kensey Nash Corp TISSUE FASTENING DEVICES
US6285897B1 (en) 1999-04-07 2001-09-04 Endonetics, Inc. Remote physiological monitoring system
EP1175176B1 (en) 1999-04-07 2010-09-22 Endonetics, Inc. Implantable monitoring probe
US6338345B1 (en) 1999-04-07 2002-01-15 Endonetics, Inc. Submucosal prosthesis delivery device
US6623494B1 (en) 1999-04-16 2003-09-23 Integrated Vascular Interventional Technologies, L.C. (Ivit, Lc) Methods and systems for intraluminally directed vascular anastomosis
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US6821285B2 (en) 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
US6494888B1 (en) 1999-06-22 2002-12-17 Ndo Surgical, Inc. Tissue reconfiguration
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US7744613B2 (en) 1999-06-25 2010-06-29 Usgi Medical, Inc. Apparatus and methods for forming and securing gastrointestinal tissue folds
US7618426B2 (en) 2002-12-11 2009-11-17 Usgi Medical, Inc. Apparatus and methods for forming gastrointestinal tissue approximations
US6626899B2 (en) 1999-06-25 2003-09-30 Nidus Medical, Llc Apparatus and methods for treating tissue
US7416554B2 (en) 2002-12-11 2008-08-26 Usgi Medical Inc Apparatus and methods for forming and securing gastrointestinal tissue folds
US20050192629A1 (en) 1999-06-25 2005-09-01 Usgi Medical Inc. Methods and apparatus for creating and regulating a gastric stoma
US7160312B2 (en) 1999-06-25 2007-01-09 Usgi Medical, Inc. Implantable artificial partition and methods of use
US20040122456A1 (en) 2002-12-11 2004-06-24 Saadat Vahid C. Methods and apparatus for gastric reduction
US7637905B2 (en) 2003-01-15 2009-12-29 Usgi Medical, Inc. Endoluminal tool deployment system
US6387104B1 (en) 1999-11-12 2002-05-14 Scimed Life Systems, Inc. Method and apparatus for endoscopic repair of the lower esophageal sphincter
EP1108400A1 (en) 1999-12-13 2001-06-20 Biomedix S.A. Removable fixation apparatus for a prosthesis in a body vessel
AU3494801A (en) 2000-02-09 2001-08-20 Eva Corp Surgical fastener
JP2004514462A (en) 2000-03-03 2004-05-20 シー・アール・バード・インク Tissue adhesion device for endoscope with multiple suction ports
CA2718633C (en) 2000-03-06 2013-01-08 Tyco Healthcare Group Lp Apparatus and method for performing a bypass procedure in a digestive system
EP1452125A3 (en) 2000-03-16 2004-10-13 Medigus Ltd Fundoplication apparatus and method
US6773452B2 (en) 2000-03-27 2004-08-10 Wilson-Cook Medical Incorporated Manometry apparatus for measuring esophageal sphincter compliance
WO2003030983A1 (en) 2001-04-06 2003-04-17 Sumitomo Bakelite Co., Ltd. Esophagus stoma button
WO2001083017A1 (en) 2000-05-02 2001-11-08 Wilson-Cook Medical, Inc. Introducer device for catheters o.t.l. with eversible sleeve
US6592596B1 (en) 2000-05-10 2003-07-15 Scimed Life Systems, Inc. Devices and related methods for securing a tissue fold
US6921361B2 (en) 2000-07-24 2005-07-26 Olympus Corporation Endoscopic instrument for forming an artificial valve
US20020082621A1 (en) 2000-09-22 2002-06-27 Schurr Marc O. Methods and devices for folding and securing tissue
US6736828B1 (en) 2000-09-29 2004-05-18 Scimed Life Systems, Inc. Method for performing endoluminal fundoplication and apparatus for use in the method
US6702735B2 (en) 2000-10-17 2004-03-09 Charlotte Margaret Kelly Device for movement along a passage
US7338522B2 (en) 2001-02-13 2008-03-04 Second Sight Medical Products, Inc. Implantable retinal electrode array configuration for minimal retinal damage and method of reducing retinal stress
US6595911B2 (en) 2001-04-03 2003-07-22 Lovuolo Michael Method and device for anchor implantation and support of bodily structures
US7020531B1 (en) 2001-05-01 2006-03-28 Intrapace, Inc. Gastric device and suction assisted method for implanting a device on a stomach wall
US6535764B2 (en) 2001-05-01 2003-03-18 Intrapace, Inc. Gastric treatment and diagnosis device and method
US7747322B2 (en) 2001-05-01 2010-06-29 Intrapace, Inc. Digestive organ retention device
US20050143784A1 (en) 2001-05-01 2005-06-30 Imran Mir A. Gastrointestinal anchor with optimal surface area
CA2447514C (en) 2001-05-18 2010-07-06 University College London A flexible device for transfixing and joining tissue
US6916332B2 (en) 2001-05-23 2005-07-12 Scimed Life Systems, Inc. Endoluminal fundoplication device and related method for installing tissue fastener
US6558400B2 (en) 2001-05-30 2003-05-06 Satiety, Inc. Obesity treatment tools and methods
US7083629B2 (en) 2001-05-30 2006-08-01 Satiety, Inc. Overtube apparatus for insertion into a body
US20020188354A1 (en) 2001-06-12 2002-12-12 Peghini Paolo Lino Device to treat obesity by obstructing gastric outlet
US6692507B2 (en) 2001-08-23 2004-02-17 Scimed Life Systems, Inc. Impermanent biocompatible fastener
US6845776B2 (en) 2001-08-27 2005-01-25 Richard S. Stack Satiation devices and methods
US7097665B2 (en) 2003-01-16 2006-08-29 Synecor, Llc Positioning tools and methods for implanting medical devices
CN101810521B (en) 2001-08-27 2015-05-13 辛尼科有限责任公司 Satiation devices and methods
US6675809B2 (en) 2001-08-27 2004-01-13 Richard S. Stack Satiation devices and methods
US20040117031A1 (en) 2001-08-27 2004-06-17 Stack Richard S. Satiation devices and methods
US7104949B2 (en) 2001-08-31 2006-09-12 Ams Research Corporation Surgical articles for placing an implant about a tubular tissue structure and methods
US6790237B2 (en) 2001-10-09 2004-09-14 Scimed Life Systems, Inc. Medical stent with a valve and related methods of manufacturing
US6740121B2 (en) 2001-11-09 2004-05-25 Boston Scientific Corporation Intragastric stent for duodenum bypass
JP4480936B2 (en) 2001-11-26 2010-06-16 オリンパス株式会社 Tissue puncture system
CA2472207A1 (en) 2002-01-09 2003-07-24 Neoguide Systems, Inc. Apparatus and method for endoscopic colectomy
US6699263B2 (en) 2002-04-05 2004-03-02 Cook Incorporated Sliding suture anchor
US7146984B2 (en) 2002-04-08 2006-12-12 Synecor, Llc Method and apparatus for modifying the exit orifice of a satiation pouch
US20050197715A1 (en) 2002-04-26 2005-09-08 Torax Medical, Inc. Methods and apparatus for implanting devices into non-sterile body lumens or organs
JP2005524485A (en) 2002-05-09 2005-08-18 ディー.イーガン トマス Gastric bypass prosthesis
US6972027B2 (en) 2002-06-26 2005-12-06 Stryker Endoscopy Soft tissue repair system
US20040133219A1 (en) 2002-07-29 2004-07-08 Peter Forsell Multi-material constriction device for forming stoma opening
EP1526803A1 (en) 2002-08-06 2005-05-04 Atropos Limited Evertable insertion tube for colonoscope
US6746460B2 (en) 2002-08-07 2004-06-08 Satiety, Inc. Intra-gastric fastening devices
US7211114B2 (en) 2002-08-26 2007-05-01 The Trustees Of Columbia University In The City Of New York Endoscopic gastric bypass
US7083630B2 (en) 2002-08-29 2006-08-01 Scimed Life Systems, Inc. Devices and methods for fastening tissue layers
US20040044364A1 (en) 2002-08-29 2004-03-04 Devries Robert Tissue fasteners and related deployment systems and methods
US8066724B2 (en) 2002-09-12 2011-11-29 Medtronic, Inc. Anastomosis apparatus and methods
US6966919B2 (en) 2002-09-20 2005-11-22 Id, Llc Instrument for applying a surgical fastener particularly for the transoral treatment of gastroesophageal reflux disease (GERD)
US7033378B2 (en) 2002-09-20 2006-04-25 Id, Llc Surgical fastener, particularly for the endoluminal treatment of gastroesophageal reflux disease (GERD)
GB0222106D0 (en) 2002-09-24 2002-10-30 Univ Dundee Body cavity inspection
US7220237B2 (en) 2002-10-23 2007-05-22 Satiety, Inc. Method and device for use in endoscopic organ procedures
US7229428B2 (en) 2002-10-23 2007-06-12 Satiety, Inc. Method and device for use in endoscopic organ procedures
US7837669B2 (en) 2002-11-01 2010-11-23 Valentx, Inc. Devices and methods for endolumenal gastrointestinal bypass
US20060015125A1 (en) 2004-05-07 2006-01-19 Paul Swain Devices and methods for gastric surgery
US7794447B2 (en) 2002-11-01 2010-09-14 Valentx, Inc. Gastrointestinal sleeve device and methods for treatment of morbid obesity
US7037344B2 (en) 2002-11-01 2006-05-02 Valentx, Inc. Apparatus and methods for treatment of morbid obesity
US20090149871A9 (en) * 2002-11-01 2009-06-11 Jonathan Kagan Devices and methods for treating morbid obesity
US20040133147A1 (en) 2002-11-06 2004-07-08 Woo Sang Hoon Intestinal bypass device to treat obesity
US8282678B2 (en) 2002-11-13 2012-10-09 Allium Medical Solutions Ltd. Endoluminal lining
US20040102855A1 (en) 2002-11-21 2004-05-27 Scimed Life Systems, Inc. Anti-reflux stent
AU2003293191B2 (en) 2002-11-29 2008-08-07 William E. Cohn Apparatus and method for manipulating tissue
US7678068B2 (en) 2002-12-02 2010-03-16 Gi Dynamics, Inc. Atraumatic delivery devices
US7025791B2 (en) 2002-12-02 2006-04-11 Gi Dynamics, Inc. Bariatric sleeve
US20070032879A1 (en) 2002-12-02 2007-02-08 Levine Andy H Anti-buckling sleeve
US7695446B2 (en) 2002-12-02 2010-04-13 Gi Dynamics, Inc. Methods of treatment using a bariatric sleeve
WO2004049982A2 (en) 2002-12-02 2004-06-17 Gi Dynamics, Inc. Bariatric sleeve
US7766973B2 (en) 2005-01-19 2010-08-03 Gi Dynamics, Inc. Eversion resistant sleeves
US7942884B2 (en) 2002-12-11 2011-05-17 Usgi Medical, Inc. Methods for reduction of a gastric lumen
US7942898B2 (en) 2002-12-11 2011-05-17 Usgi Medical, Inc. Delivery systems and methods for gastric reduction
US20040249367A1 (en) 2003-01-15 2004-12-09 Usgi Medical Corp. Endoluminal tool deployment system
US20040143342A1 (en) 2003-01-16 2004-07-22 Stack Richard S. Satiation pouches and methods of use
US20040181242A1 (en) 2003-03-12 2004-09-16 Stack Richard S. Articulated suturing system
US20040249362A1 (en) 2003-03-28 2004-12-09 Gi Dynamics, Inc. Enzyme sleeve
DE602004019505D1 (en) 2003-03-28 2009-04-02 Gi Dynamics Inc DEVICES AGAINST GRAVITY
GB0307715D0 (en) 2003-04-03 2003-05-07 Ethicon Endo Surgery Inc Guide wire structure for insertion into an internal space
US20070225555A1 (en) 2003-05-16 2007-09-27 David Stefanchik Method for deploying a medical device
US7731757B2 (en) 2003-06-01 2010-06-08 Reflux Corporation Obesity treatment
US8048169B2 (en) 2003-07-28 2011-11-01 Baronova, Inc. Pyloric valve obstructing devices and methods
US20090259236A2 (en) 2003-07-28 2009-10-15 Baronova, Inc. Gastric retaining devices and methods
US6994095B2 (en) 2003-07-28 2006-02-07 Medventure Associates Iv Pyloric valve corking device and method
WO2005011535A2 (en) 2003-07-31 2005-02-10 Cook Incorporated Prosthetic valve for implantation in a body vessel
US7314489B2 (en) 2003-08-20 2008-01-01 Ethicon Endo-Surgery, Inc. Method and apparatus to facilitate nutritional malabsorption
CA2537307A1 (en) 2003-09-02 2005-04-14 Biomedix S.A. Gastrointestinal anti-reflux prosthesis apparatus and method
US7309341B2 (en) 2003-09-30 2007-12-18 Ethicon Endo-Surgery, Inc. Single lumen anastomosis applier for self-deploying fastener
US20050075654A1 (en) 2003-10-06 2005-04-07 Brian Kelleher Methods and devices for soft tissue securement
US20050247320A1 (en) 2003-10-10 2005-11-10 Stack Richard S Devices and methods for retaining a gastro-esophageal implant
US20050080444A1 (en) 2003-10-14 2005-04-14 Kraemer Stefan J.M. Transesophageal gastric reduction device, system and method
US20050085787A1 (en) 2003-10-17 2005-04-21 Laufer Michael D. Minimally invasive gastrointestinal bypass
JP4669480B2 (en) 2003-12-09 2011-04-13 ジーアイ・ダイナミックス・インコーポレーテッド Intestinal sleeve
EP1713402B1 (en) 2004-02-13 2018-07-04 Ethicon Endo-Surgery, Inc. Device for reducing stomach volume
US7632287B2 (en) 2004-02-20 2009-12-15 Endogastric Solutions, Inc. Tissue fixation devices and assemblies for deploying the same
US8585771B2 (en) 2004-02-26 2013-11-19 Endosphere, Inc. Methods and devices to curb appetite and/or to reduce food intake
US20050197714A1 (en) 2004-03-02 2005-09-08 Sayet Peter H. System, system devices, and methods for regulating nutrient absorption and caloric intake
US8628547B2 (en) 2004-03-09 2014-01-14 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
CA2561193A1 (en) 2004-03-26 2005-10-20 Satiety, Inc. Systems and methods for treating obesity
US20050228413A1 (en) 2004-04-12 2005-10-13 Binmoeller Kenneth F Automated transluminal tissue targeting and anchoring devices and methods
WO2005105003A1 (en) 2004-04-26 2005-11-10 Synecor, Llc Restrictive and/or obstructive implant for inducing weight loss
JP4934024B2 (en) 2004-05-03 2012-05-16 フルフィリウム, インコーポレイテッド Method and system for controlling stomach volume
EP1750595A4 (en) 2004-05-07 2008-10-22 Valentx Inc Devices and methods for attaching an endolumenal gastrointestinal implant
US7520884B2 (en) 2004-05-07 2009-04-21 Usgi Medical Inc. Methods for performing gastroplasty
US20060020254A1 (en) 2004-05-10 2006-01-26 Hoffmann Gerard V Suction assisted tissue plication device and method of use
WO2005112785A2 (en) 2004-05-14 2005-12-01 Ethicon Endo-Surgery, Inc. Suture locking and cutting devices and methods
US7678135B2 (en) 2004-06-09 2010-03-16 Usgi Medical, Inc. Compressible tissue anchor assemblies
US7972292B2 (en) 2005-07-06 2011-07-05 Percutaneous Systems, Inc. Methods and apparatus for deploying ureteral stents
WO2006016894A1 (en) 2004-07-09 2006-02-16 Gi Dynamics, Inc. Methods and devices for placing a gastrointestinal sleeve
US20060020277A1 (en) 2004-07-20 2006-01-26 Gostout Christopher J Gastric reshaping devices and methods
US8172857B2 (en) 2004-08-27 2012-05-08 Davol, Inc. Endoscopic tissue apposition device and method of use
US7651508B2 (en) * 2004-08-31 2010-01-26 Vierk Dan A DiamAbrasion system
US7244270B2 (en) 2004-09-16 2007-07-17 Evera Medical Systems and devices for soft tissue augmentation
WO2006034062A1 (en) 2004-09-17 2006-03-30 Gi Dynamics, Inc. Gastrointestinal anchor
US20060155375A1 (en) 2004-09-27 2006-07-13 Jonathan Kagan Devices and methods for attachment of a gastrointestinal sleeve
US7780592B2 (en) 2004-10-29 2010-08-24 Medtronic, Inc. Distal portion of an endoscopic delivery system
US7771382B2 (en) 2005-01-19 2010-08-10 Gi Dynamics, Inc. Resistive anti-obesity devices
US7699863B2 (en) 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
EP1871238A2 (en) 2005-04-14 2008-01-02 Biomedix S. A. Article, system, and method for securing medical device to tissue or organ
US20060253126A1 (en) 2005-05-04 2006-11-09 Bernard Medical, Llc Endoluminal suturing device and method
US7666180B2 (en) 2005-05-20 2010-02-23 Tyco Healthcare Group Lp Gastric restrictor assembly and method of use
US20060264982A1 (en) 2005-05-20 2006-11-23 Viola Frank J Gastric restrictor assembly and method of use
US8932208B2 (en) 2005-05-26 2015-01-13 Maquet Cardiovascular Llc Apparatus and methods for performing minimally-invasive surgical procedures
US7976488B2 (en) 2005-06-08 2011-07-12 Gi Dynamics, Inc. Gastrointestinal anchor compliance
US20070016262A1 (en) 2005-07-13 2007-01-18 Betastim, Ltd. Gi and pancreatic device for treating obesity and diabetes
EP2001401A4 (en) 2005-09-09 2009-01-07 Biomedix Sa Medical device and method for controlling obesity
US9055942B2 (en) 2005-10-03 2015-06-16 Boston Scienctific Scimed, Inc. Endoscopic plication devices and methods
US7509175B2 (en) 2006-08-03 2009-03-24 Intrapace, Inc. Method and devices for stimulation of an organ with the use of a transectionally placed guide wire
US20080221597A1 (en) 2005-10-12 2008-09-11 Wallace Jeffrey M Methods and devices for intragastrointestinal fixation
US20070106233A1 (en) 2005-10-20 2007-05-10 Percutaneous Systems, Inc. Systems and methods for dilating and accessing body lumens
US20070100367A1 (en) 2005-10-31 2007-05-03 Quijano Rodolfo C Intragastric space filler
US7881797B2 (en) * 2006-04-25 2011-02-01 Valentx, Inc. Methods and devices for gastrointestinal stimulation
WO2007137228A2 (en) 2006-05-19 2007-11-29 Norman Godin Medical staple, system and methods of use
US8870916B2 (en) 2006-07-07 2014-10-28 USGI Medical, Inc Low profile tissue anchors, tissue anchor systems, and methods for their delivery and use
US20080058840A1 (en) 2006-09-01 2008-03-06 Albrecht Thomas E Implantable coil for insertion into a hollow body organ
US8109895B2 (en) 2006-09-02 2012-02-07 Barosense, Inc. Intestinal sleeves and associated deployment systems and methods
EP2068719B1 (en) 2006-09-15 2017-10-25 Boston Scientific Scimed, Inc. System for anchoring stomach implant
US8118774B2 (en) 2006-09-25 2012-02-21 Valentx, Inc. Toposcopic access and delivery devices
US8801647B2 (en) 2007-02-22 2014-08-12 Gi Dynamics, Inc. Use of a gastrointestinal sleeve to treat bariatric surgery fistulas and leaks
US8226602B2 (en) 2007-03-30 2012-07-24 Reshape Medical, Inc. Intragastric balloon system and therapeutic processes and products
US9717584B2 (en) 2007-04-13 2017-08-01 W. L. Gore & Associates, Inc. Medical apparatus and method of making the same
US9642693B2 (en) 2007-04-13 2017-05-09 W. L. Gore & Associates, Inc. Medical apparatus and method of making the same
US20080255678A1 (en) 2007-04-13 2008-10-16 Cully Edward H Medical apparatus and method of making the same
US20090012544A1 (en) 2007-06-08 2009-01-08 Valen Tx, Inc. Gastrointestinal bypass sleeve as an adjunct to bariatric surgery
WO2008154450A1 (en) 2007-06-08 2008-12-18 Valentx, Inc. Methods and devices for intragastric support of functional or prosthetic gastrointestinal devices
EP2157919A4 (en) 2007-06-11 2011-06-22 Valentx Inc Endoscopic delivery devices and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092892A1 (en) * 2002-11-01 2004-05-13 Jonathan Kagan Apparatus and methods for treatment of morbid obesity
US20060265021A1 (en) * 2004-03-16 2006-11-23 Medtronic, Inc. Intra-Luminal Device for Gastrointestinal Electrical Stimulation
US20060247718A1 (en) * 2005-04-28 2006-11-02 Medtronic, Inc. Dual mode electrical stimulation to treat obesity

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962278B2 (en) 2009-04-03 2018-05-08 Metamodix, Inc. Modular gastrointestinal prostheses
US9044300B2 (en) 2009-04-03 2015-06-02 Metamodix, Inc. Gastrointestinal prostheses
US9173760B2 (en) 2009-04-03 2015-11-03 Metamodix, Inc. Delivery devices and methods for gastrointestinal implants
US9278019B2 (en) 2009-04-03 2016-03-08 Metamodix, Inc Anchors and methods for intestinal bypass sleeves
US10322021B2 (en) 2009-04-03 2019-06-18 Metamodix, Inc. Delivery devices and methods for gastrointestinal implants
US8702642B2 (en) 2009-07-10 2014-04-22 Metamodix, Inc. External anchoring configurations for modular gastrointestinal prostheses
US10159699B2 (en) 2013-01-15 2018-12-25 Metamodix, Inc. System and method for affecting intestinal microbial flora
US11793839B2 (en) 2013-01-15 2023-10-24 Metamodix, Inc. System and method for affecting intestinal microbial flora
US10413209B2 (en) 2014-02-12 2019-09-17 The Methodist Hospital Method and apparatus for identifying the ureter during a minimally-invasive procedure
US20170252195A1 (en) 2016-03-03 2017-09-07 Metamodix, Inc. Pyloric anchors and methods for intestinal bypass sleeves
US10729573B2 (en) 2016-03-03 2020-08-04 Metamodix, Inc. Pyloric anchors and methods for intestinal bypass sleeves
US9622897B1 (en) 2016-03-03 2017-04-18 Metamodix, Inc. Pyloric anchors and methods for intestinal bypass sleeves
US10751209B2 (en) 2016-05-19 2020-08-25 Metamodix, Inc. Pyloric anchor retrieval tools and methods
US11666470B2 (en) 2016-05-19 2023-06-06 Metamodix, Inc Pyloric anchor retrieval tools and methods

Also Published As

Publication number Publication date
US20080058887A1 (en) 2008-03-06
US7881797B2 (en) 2011-02-01
US20110125211A1 (en) 2011-05-26
WO2007127209A3 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
US7881797B2 (en) Methods and devices for gastrointestinal stimulation
US8012135B2 (en) Attachment cuff for gastrointestinal implant
US7846138B2 (en) Cuff and sleeve system for gastrointestinal bypass
US20200000616A1 (en) Delivery devices and methods for gastrointestinal implants
AU2010271294B2 (en) External anchoring configurations for modular gastrointestinal prostheses
JP5191489B2 (en) Device and method for changing feeding behavior
US7580751B2 (en) Intra-luminal device for gastrointestinal stimulation
US20070060932A1 (en) Devices and methods for retaining a gastro-esophageal implant
AU2012315575B2 (en) Delivery devices and methods for gastrointestinal implants
EP2010270A2 (en) Devices and methods for endolumenal gastrointestinal bypass
EP2561840B1 (en) Device for anchoring an endoluminal sleeve in the GI tract

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07755978

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07755978

Country of ref document: EP

Kind code of ref document: A2